2016 ANNUAL REPORT - CRI - Cancer Research Institute · CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT 1 OUR MISSION: ... aidong Dong, M.D., ... The Anna-Maria Kellen Clinical Accelerator

2016 ANNUAL REPORT

IN 2016, CRI SUPPORTED LABORATORY, TRANSLATIONAL, AND CLINICAL RESEARCH IN 13 COUNTRIES, INCLUDING 20 U.S. STATES.

1 From Our Leadership

2 Postdoctoral Fellows

4 Translational Research

6 Clinical Accelerator

8 Drug Development

10 Scientific Dialogue

12 Awareness & Education 14 Awards & Honors

Just five years ago, when talking about outcomes of patients treated for late-stage cancers, “cure” wasn’t a word our scientists were likely to use. Today, the outlook

is significantly better, with cancer immunotherapy now offering patients a real chance—not only at surviving longer, but also at living better without the debilitating side effects often seen with conventional cancer treatments. At last, we can say that cures for cancer are within reach.

This didn’t happen overnight. It has taken a long view of progress and decades of research to build a foundation for the new therapies available to patients today. Lifesaving drugs like the FDA-approved immunotherapies Yervoy®, Opdivo®, Keytruda®, Imlygic®, and others are built upon fundamental knowledge of the immune system, its components, and how they function. This knowledge was hard won by a global community of immunologists and tumor immunologists, many of whom have relied on funding from the Cancer Research Institute to carry out their important work.

In fiscal year 2016 (July 1, 2015, to June 30, 2016), we continued to push the limits of human knowledge and open the way for new and more effective immunotherapies by awarding over $23.6 million to support highly promising laboratory, translational, and clinical research around the world.

We also recognize the need to help patients and their caregivers navigate what can be an overwhelming introduction to this new treatment approach. In 2016, we invested in educational programming to provide them trusted information and connect them to immunotherapy clinical trials. And as part of our Cancer Immunotherapy Month awareness campaign in June, we introduced more than 3.8 million people worldwide to the exciting progress being made today thanks to immunotherapy breakthroughs.

We are proud that we are able to make these important contributions to the global cancer research and patient communities while also maintaining our high ratings with charity watchdogs, including four out of four stars from Charity Navigator and membership within the Better Business Bureau’s Wise Giving Alliance, among others.

None of this lifesaving work would be possible without the generous support of our donors like you, on whom we rely. We extend our heartfelt thanks on behalf of the thousands of CRI-funded scientists and the millions of cancer patients worldwide who may benefit from your support.

ANDREW K. TSAICo-Chairman of the Board

PAUL C. SHIVERICKCo-Chairman of the Board

JAMES P. ALLISON, PH.D.Director, Scientific Advisory Council

JILL O’DONNELL-TORMEY, PH.D.CEO and Director of Scientific Affairs

CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT 1

OUR MISSION:SAVE MORE LIVES We fuel the discovery and development of powerful immunotherapies for all types of cancer.Established in 1953, the Cancer Research Institute (CRI) is a 501(c)(3) nonprofit organization dedicated to harnessing the immune system’s power to conquer all cancers. We fund the most innovative research of young scientists, invest in clinical studies of promising new treatments, and provide patients and caregivers with information on the latest advances in cancer immunotherapy. With more than 60 years of experience funding research on the immune system and cancer, CRI is leading the way and ushering in a new era when patients, with all types of cancer, can be treated and potentially cured with immunotherapy.

16 Fiscal Year 2016 Grants & Awards

30 Fundraising

32 Donors

46 Financial Highlights

48 Governance & Guidance

58 Ways to Give

From Our Leadership

The CRI Irvington Postdoctoral Fellowship Program provides training and financial support to young scientists working in the laboratories of leading cancer immunologists around the world. Fellowships provide up to $175,500 over three years.

PO

ST

DO

CT

OR

AL

FE

LL

OW

S

Our postdoctoral fellows are the best and the brightest, bringing new energy to tackle the most pressing areas of research today. Their investigations deepen our knowledge of the immune

system and lay the foundation for new immunotherapies for all types of cancer. In the past year:

Leticia Corrales, Ph.D., of the University of Chicago, in Chicago, IL, engineered a small molecule of PD-1 and demonstrated its effectiveness in treating both small and large colorectal cancer tumors.

Rony Dahan, Ph.D., of The Rockefeller University, in New York, NY, demonstrated how the tail region of checkpoint inhibitor antibodies can affect immunotherapy responses, providing key insights to support the development of next-generation checkpoint inhibitors.

P.C. Dave P. Dingal, Ph.D., of Stanford University School of Medicine, in Stanford, CA, created a system that allows researchers to manipulate the activity of genes to better characterize and understand the immune system’s dynamics.

Bengt Martin Gustavsson, Ph.D., of the University of California, San Diego, in San Diego, CA, developed new ways to design and analyze the binding affinity of a key immune molecule, called a chemokine, to enable more effective drug design.

Jiazhi Hu, Ph.D., of the Boston Children’s Hospital, in Boston, MA, discovered how enzymes called RAGs can cause improper DNA rearrangements that have been implicated in B cell lymphoma, a deadly type of blood cancer.

Helene M. Salmon, Ph.D., of the Icahn School of Medicine at Mount Sinai, in New York, NY, revealed how dendritic cells coordinate anti-melanoma responses, and developed an approach to enhance their anti-cancer activity in combination with checkpoint inhibitors.

29 NEW GRANTS

$5.1MILLION AWARDED

Powering Innovation


Margaret K. Callahan, M.D., Ph.D., recently the Lloyd J. Old Memorial Fellow at Memorial Sloan Kettering Cancer Center in New York, NY, demonstrated in a phase III clinical trial

for metastatic melanoma that combining the immunotherapies

RONY DAHAN, BENGT MARTIN GUSTAVSSON, P.C. DAVE P. DINGAL, AND MARGARET K. CALLAHAN

ipilimumab (Yervoy®) and nivolumab (Opdivo®) resulted in significantly longer progression-free survival than ipilimumab alone. In fiscal year 2016, the combination received FDA approval as a first-line treatment for melanoma.

IMPACT FDA ApprovalFor a complete list of all 102 postdoctoral fellows active in FY2016, go to page 18

CRI is at the forefront of supporting innovative and highly promising research. As a postdoctoral fellow, I relied on CRI’s funding of my basic research, considered at the time by some as lacking cancer relevance. Yet, it turned out that it’s now one of the main focuses in cancer therapy development.

Estela P. Jacinto, Ph.D. Associate Professor, Rutgers UniversityCRI Irvington Postdoctoral Fellow, 1999-2002

TR

AN

SL

AT

ION

AL

RE

SE

AR

CH

12 NEW GRANTS

$2.4MILLION AWARDED

The Clinic and Laboratory Integration Program (CLIP) supports scientists conducting translational research aimed at improving the effectiveness of immunotherapies. CLIP grants provide up to $200,000 over two years.

Recent clinical outcomes from immunotherapy trials have generated new scientific questions and high demand for research funding. CRI established CLIP to facilitate better dialogue between the

laboratory and clinic. By channeling support into this “translational” area, CRI supports an iterative research loop that can lead to new and more effective immunotherapies.

Bridging Basic and Clinical Science


Juan R. Cubillos-Ruiz, Ph.D.Assistant Professor of Microbiology and Immunology, Weill Cornell Medicine, New York, NY

While immune cells can slow and even halt ovarian cancer progression, immunosuppressive factors in the tumor environment can reduce their potency. Cubillos-Ruiz is investigating a newly recognized fatty acid, or lipid, that enables ovarian tumors to evade immune attack. He will study whether blocking the lipid’s receptor can enhance anti-tumor immune responses. Promising results could lead to therapeutic drug combinations that improve survival in ovarian cancer patients.

Amanda Lund, Ph.D.Assistant Professor of Cell & Developmental Biology; Molecular Microbiology & Immunology; and Dermatology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR

Lund is working to improve our understanding of how lymph-transporting vessels affect our immune system’s ability to carry out anti-tumor immune responses against melanoma. Abnormal lymphatic growth is associated with cancer, and Lund hypothesizes that tumors may be “hijacking” these vessels to escape the immune system. Lund’s work may enhance immunotherapy approaches that target these vessels and improve survival in melanoma patients.

It’s difficult to secure funding for applied research projects like ours, and this unique grant allows us to pursue our efforts to improve the effectiveness of cancer immunotherapy.

Michael S. Goldberg, Ph.D. Assistant Professor of Cancer Immunology & Virology, Dana-Farber Cancer InstituteCLIP Investigator, 2014-2016

Mark J. Smyth, Ph.D., FAHMS Senior Scientist and Immunology Coordinator, QIMR Berghofer Medical Research Institute,Brisbane, Australia

Smyth is exploring a strategy that targets CD96, a receptor that can prevent immune cells like natural killer (NK) cells from eliminating cancer. He aims to determine whether blocking CD96 with an antibody, given alone and in combination with other treatments, can improve anti-tumor immunity. Smyth’s findings may lead to strategies to reduce tumor metastases and treat patients successfully.

Haidong Dong, M.D., Ph.D., a 2015-2017 CLIP investigator and associate professor of immunology at the Mayo Clinic in Rochester, MN, discovered that the Bim biomarker on T

cells can predict how well patients might potentially respond to

immunotherapy, and provides a way to observe ongoing anti-cancer immune responses. If validated, this biomarker will help doctors to monitor an immunotherapy’s effectiveness in patients.

IMPACT Power of Biomarkers

Seeking Out Immunosuppression in Ovarian Cancer

Novel Target for Cancer Immunotherapy

Beyond PD-1: In Search of a New Checkpoint Inhibitor

For a complete list of all CLIP investigators active in FY2016, go to page 22

The Anna-Maria Kellen Clinical Accelerator is CRI’s venture philanthropy program designed to help spur the creation of next-generation combination cancer immunotherapies through partnerships with academia and industry.

CL

INIC

AL

AC

CE

LE

RA

TO

R

CRI’s clinical program fosters collaboration across top academic research groups, biopharma companies, and nonprofit partners to design, conduct, manage, and fund

scientifically-driven clinical trials with high potential for success. These trials make available to patients new and promising treatment combinations that they otherwise could not access.

Prioritized studies are launched with a comprehensive set of nonprofit resources and a unique IP model that facilitates access to top drugs from different companies. Clinical Accelerator currently has more than 15 significant industry and nonprofit partners.

The model is powered by a nonprofit venture capital fund, which enables it to achieve significant leverage via co-investments and is structured to become self-sustaining over time via returns on investment back to the charity as supported drugs demonstrate their effectiveness. The backbone of the program, the CVC Clinical Trials Network, is powered by more than 80 clinician scientists around the world and is managed jointly by CRI and its partner, Ludwig Cancer Research.

It’s a win-win-win model: cancer patients gain access to promising new treatment options; scientists gain extraordinary clinical research and publication opportunities; and company partners gain valuable investment of nonprofit resources and expertise into their drugs.

2 NEW TRIALS

4 EXPANDED TRIALS

$15.6MILLION AWARDED

A New Clinical Discovery Model


CRI’s Clinical Accelerator allows me to provide cutting-edge immunotherapy combinations to patients with glioblastoma, a type of brain cancer that is difficult to treat and which may be a promising target for immunotherapy.

David A. Reardon, M.D. Clinical Director, Center for Neuro-Oncology, Dana-Farber Cancer Institute CVC Clinical Trials Network Member, 2012-present

To date, Clinical Accelerator investments have supported 10 phase I and II cancer immunotherapy clinical trials. These trials are bringing novel immunotherapy combinations into

the clinic and will ultimately treat over 800 patients spanning

For a complete list of all active CRI-funded clinical trials, go to page 25

20 types of cancer, including very hard-to-treat cancers like glioblastoma, a type of brain cancer, triple-negative breast cancer, and colorectal cancer.

IMPACT Hope for Cancer Patients

The Cancer Immunotherapy Consortium (CIC) is a think tank of industry leaders from the cancer immunotherapy field who seek solutions to challenges in late-stage drug development, with the goal of accelerating patient benefit.

DR

UG

D

EV

EL

OP

ME

NT

The CIC was founded in 2002 as an international membership association of pharmaceutical and biotechnology companies and academic institutions with a common interest in

immunotherapy research and development, with the ultimate goal of making cancer immunotherapies part of the standard-of-care in oncology.

With the 2011 FDA approval of ipilimumab (Yervoy®), an immune checkpoint inhibitor drug, the first milestone toward this goal was achieved. Given the substantial increase in development activity and clinical success of other immunotherapy agents that followed, and in an effort to continue to provide maximum value to the rapidly evolving field, the direction of the CIC was re-set to become a “think tank” that would convene and tackle topics of importance to the continued development of cancer immunotherapies.

The CIC now acts as a neutral platform whereby industry representatives work together to discuss important issues and collectively facilitate solutions to challenges in late-stage drug development, with the goal of accelerating patient benefit. Outcomes will be available to all stakeholders in the field through publishing of CIC proceedings. Current topics under review include application of immune-related Response Criteria (irRC) across clinical studies in multiple tumor types, and second-generation biomarkers.

23PUBLICATIONS TO DATE

12INDUSTRYREPRESENTATIVES

Harnessing Industry Expertise


Through the CIC, companies with immunotherapies in development can work together toward the same goal, finding solutions that will help the entire industry and, ultimately, cancer patients.

Daniel S. Chen, M.D., Ph.D. Vice President, Global Head of Cancer Immunotherapy Development, Genentech/Roche Co-Chairman, CIC Steering Committee

In 2016, CIC Steering Committee members identified important next steps toward the development of shared definitions of patient outcomes that can be used across different company-

sponsored drug trials when describing tumor progression within the context of immunotherapy treatment. The development

of common methods for assessing and reporting patient outcomes may allow for improved trial design and generation of data that facilitates FDA review of new immunotherapies.

IMPACT Finding a Common LanguageTo learn more about the Cancer Immunotherapy Consortium, visit cancerresearch.org/cic

The CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference is a scientific meeting devoted to exploring the latest research in cancer immunology and immunotherapy. It attracts clinicians, scientists, government regulators, drug developers, and patient groups.

SC

IEN

TIF

IC

DIA

LO

GU

E

W ith the explosion of interest in cancer immunotherapy and the proliferation of scientific meetings in the field, the Cancer Research Institute, along with the Association

for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR), decided to join forces to sponsor the International Cancer Immunotherapy Conference devoted to exploring the latest research in cancer immunology and immunotherapy.

The theme of the inaugural September 2015 meeting, held in New York City, was “Translating Science Into Survival,” and featured over 60 presentations from leaders in immunology and cancer immunotherapy. Emerging themes included new genetic targets for personalized immunotherapies, the relationship between the microbiome and cancer, and new targets for checkpoint blockade, chimeric antigen receptor (CAR) treatment, and vaccine therapy. There was also a snapshot of the regulatory landscape for cell and gene therapy, biomarkers and their function in patient selection, imaging and its role in targeting the anti-tumor response, and immunotherapy trial designs.

1,400+ PARTICIPANTS

375POSTERSPRESENTED

Translating Science Into Survival


The International Cancer Immunotherapy Conference brings together prominent and promising researchers in cancer immunology and immunotherapy from around the world for one of the most important meetings of its kind.

Steven A. Rosenberg, M.D., Ph.D.Chief, Surgery Branch, Senior Investigator, and Head, Tumor Immunology Section, National Cancer Institute, NIHKeynote Speaker, Inaugural International Cancer Immunotherapy Conference

The September 2015 conference attracted more than 1,400 participants from 38 countries across Asia, Australia, Europe, North America, and South America. More than 375 scientists

presented their research at the meeting’s poster sessions, and CRI postdoctoral fellows and other meeting participants took

To learn more about the conference, visit cancerimmunotherapyconference.org

advantage of the many networking opportunities. Due to high demand, the organizers hosted a second conference in 2016 in New York City, and a third will take place in Mainz/Frankfurt, Germany in 2017.

IMPACT Convening a Global Audience

CRI is committed to educating patients, caregivers, and broader public audiences on important developments in cancer immunotherapy research and treatment.

AW

AR

EN

ES

S

& E

DU

CA

TIO

N

C ancer immunotherapy is a fast-moving field, and keeping up can be challenging. We provide educational programs and awareness initiatives designed to reach people who are unaware

of immunotherapy’s promise and connect them to resources and communities that can help them on their treatment journeys.

Preferred Destination for Trusted InformationMore than 1 million website visitors per year rely on free information we provide on immunotherapy research and treatment for more than 20 different types of cancer.

Immunotherapy Clinical Trial FinderThis fully supported service, the only one of its kind devoted exclusively to cancer immunotherapy trials, has helped more than 4,500 people take the first step in exploring their immunotherapy options.

Cancer Immunotherapy MonthThis series of educational, social, and athletic events in June promotes awareness of cancer immunotherapy and raises funds to support lifesaving research. Our most recent June activities featured:

• Immunotherapy Patient Stories: Inspiring videos of patients sharing their experiences with cancer immunotherapy

• Cancer Immunotherapy and You: Free webinars for patients and caregivers featuring immunotherapy experts and interactive Q&A

• ImmunotherapyandChemotherapy:What’stheDifference?: Animated video explaining how these treatments work as well as their potential benefits and possible side effects

• Ask a Scientist: Short videos inviting immunotherapy experts to address the most frequently asked questions from patients

• What Cancer Patients Should Know: Latest Immunotherapy News from ASCO 2016: An expert panel discussing new developments in cancer immunotherapy research and treatment from the world’s largest cancer conference

3.8 MILLION PEOPLE REACHED

500kVIEWS OF EDUCATIONALPROGRAMMING

Connecting Patients, Saving Lives


Our education and public awareness programming reached more than 3.8 million people last year, introducing them to cancer immunotherapy breakthroughs and patient

stories of hope, and providing them with information that can

To learn more, visit cancerresearch.org/june

help them or a loved one during a cancer diagnosis. Health care professionals such as oncology nurses and community oncologists also found our many resources helpful for their ongoing professional education.

IMPACT Awareness

Social Media and Offline Special Events• #WhiteOutCancer Day: This global social media event invited

people to show their support for cancer immunotherapy research by wearing white and posting a “selfie” to Facebook, Twitter, and Instagram or by uploading a personalized message with a photo to our website at whiteoutcancer.com

• Answer to Cancer Cycling Event: On June 25, 2016, more than 220 cyclists rode 100, 50, or 25 miles through historic West Point and the surrounding Lower Hudson Valley in New York during this inaugural fund- and awareness-raising event sponsored by Bristol-Myers Squibb

• Corporate Events: Participating companies around the world engaged thousands of their employees in day-long awareness, education, and fundraising activities designed to highlight progress in cancer treatment and promote company commitment to social responsibility and employee health

Thank you to all of our generous partners and supportersAbbvie; Agenus; Basin Holdings; Bristol-Myers Squibb Company; Brooklyn Brewery; Celldex Therapeutics, Inc.; Clayton, Dubilier & Rice, LLC; Debevoise & Plimpton LLP; Finish Line Physical Therapy; Genentech; Hincapie Sportswear; Holowesko Citadel; Horseneck Wines & Liquors; Hudson Valley Harvest; Inovio Pharmaceuticals; LabAnswer and its employees; Merck, known as MSD outside the U.S. and Canada; Mitsubishi UFJ Securities; Nestle Waters North America; NewLink Genetics; PPD; Regeneron Pharmaceuticals; Reynolds Cycling LLC; The Sweat Life; Tailwind Endurance; and USA Cycling

The more people who enter trials, the more people who are educated, the more power we as patients have.

Stephen E. colorectal cancer survivor

Each year, the Cancer Research Institute honors individuals and organizations that have made important contributions to the field of cancer immunotherapy.

AW

AR

DS

&

HO

NO

RS

The William B. Coley Award for Distinguished Research in Basic Immunology Alexander Y. Rudensky, Ph.D., Memorial Sloan Kettering Cancer Center, Howard Hughes Medical Institute, New York, NY, for his contributions to our understanding of regulatory T cells, which play an important role in restraining immune responses and inflammation

The William B. Coley Award for Distinguished Research in Tumor Immunology Glenn Dranoff, M.D., Novartis Institutes for BioMedical Research, Cambridge, MA, for his many contributions to the development of cancer immunotherapies, including the design and testing of the therapeutic cancer vaccine GVAX

The Frederick W. Alt Award for New Discoveries in Immunology Nina Bhardwaj, M.D., Ph.D., Icahn School of Medicine at Mount Sinai, New York, NY, for her pioneering work on dendritic cells, which are key antigen-presenting cells that play an important role in starting the immune response

AACR-CRI Lloyd J. Old Award in Cancer Immunotherapy Ronald Levy, M.D., Stanford University School of Medicine, Stanford, CA, for his work on developing rituximab (Rituxan®), the first monoclonal antibody to be approved by the FDA, in 1997

The Oliver R. Grace Award for Distinguished Service in Advancing Cancer Research Kenneth C. Frazier, Chairman and CEO, Merck & Co., for advancing immuno-oncology research and drug development

Lauren S. Veronis, Trustee, Cancer Research Institute, and Former President, Irvington Institute for Immunological Research, for her many years of devotion to advancing immunological research through her leadership and fundraising efforts

Recognizing Excellence


To view all CRI award recipients, visit cancerresearch.org/honorees

I’ve always thought immunotherapy had an enormous potential to create an ongoing engine of opposition to cancers.

Bill Clinton 42nd President of the United StatesKeynote Speaker, CRI 39th Annual Awards Dinner

THE METROPOLITAN CLUB IN NEW YORK, NY; KENNETH C. FRAZIER AND CRI TRUSTEE PAUL C. SHIVERICK; ALEXANDER Y. RUDENSKY AND CRI SCIENTIFIC ADVISOR PHILIP D. GREENBERG; AND LAUREN S. VERONIS AND CRI CEO AND DIRECTOR OF SCIENTIFIC AFFAIRS JILL O’DONNELL-TORMEY

155 SCIENTIFIC AND LAY INDIVIDUALS AND ORGANIZATIONS RECOGNIZED TO DATE

In fiscal year 2016 (July 1, 2015, to June 30, 2016), the Cancer Research Institute awarded more than $23.6 million for cancer immunology research and cancer immunotherapy clinical development.

FIS

CA

L Y

EA

R 2

01

6

GR

AN

TS

& A

WA

RD

S Funding the Best Science


22 STATES

13 COUNTRIES

83INSTITUTIONS

20+ CANCERS UNDER STUDY

* Denotes grants newly awarded in fiscal year 2016. All others are active grants awarded in previous years.


STUDENT TRAINING AND RESEARCH IN TUMOR IMMUNOLOGY (START) PROGRAMTwo-year awards that attract bright young minds to rewarding careers as cancer immunologists by funding graduate studies in tumor immunology at top universities.

Massachusetts General Hospital, Boston, MAAlexandria HuynhThe role of PTEN in regulatory T cell stability and immune surveillance

Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PAThomas Chia Ting FungRole of innate lymphoid cell-controlled intestinal barrier function in hepatocellular carcinoma

University of California, Berkeley, Berkeley, CAThornton William ThompsonThe role of oncogene-induced senescence in promoting anti-tumor immune responsesF.M. Kirby Fellow

PREDOCTORAL EMPHASIS PATHWAYS IN TUMOR IMMUNOLOGYFour-year awards to universities to support establishment and maintenance of tumor immunology training courses for graduate students.

Johns Hopkins University School of Medicine, Baltimore, MDDirector: Charles G. Drake, M.D., Ph.D.

University of Colorado, Denver, CODirectors: John Kappler, Ph.D., and Philippa Marrack, Ph.D.Immunology / Tumor Immunology Training Course

Lomonosov Moscow State University, Moscow, RussiaSergei A. Nedospasov, Ph.D., D.Sc.Lloyd J. Old Advanced Training Program in Immunology and Oncoimmunology

CRI IRVINGTON POSTDOCTORAL FELLOWSHIP PROGRAMThree-year awards that further the career development and advanced laboratory research of promising postdoctoral fellows working under the mentorship of world-class immunologists and tumor immunologists.

Boston Children’s Hospital, Boston, MAZhaoqing Ba, Ph.D.*Mechanisms that mediate intra-locus and inter-locus regulation of V(D)J recombination at immunoglobulin light chain lociSamuel and Ruth Engelberg Fellow

Bradley Wayne Blaser, M.D., Ph.D.Immunologic regulation of hematopoietic stem cell engraftment

Liron David, Ph.D.Molecular elucidation of the CBM complex in NFκĸB activation by antigen receptors

Jiazhi Hu, Ph.D.Mechanisms that target AID for antibody gene diversification and for oncogenic chromosomal translocationsRobertson Foundation Fellow

Cheng-Sheng Lee, Ph.D.*Elucidating the mechanism and the impact of RAG tracking

Qi Qiao, Ph.D.Mechanistic elucidation of activation-induced deaminase in immunity and cancer

Heng Ru, Ph.D.Structural and biochemical studies of the antigen receptor gene recombination machinery

Liman Zhang, Ph.D.*Structural studies of NAIP/NLRC4 inflammasomes in immunity and cancer

Broad Institute of MIT and Harvard, Cambridge, MALe Cong, Ph.D.*Dissection of cellular states and transcriptional networks regulating innate immunity during tumorigenesis

Livnat Jerby, Ph.D.*Integrating CRISPR with single-cell RNA-sequencing to map the underlying circuits of immune evasion mechanisms in melanomaThe Hearst Foundations Fellow

California Institute of Technology, Pasadena, CAAndrew I. Flyak, Ph.D.*The structural basis of hepatitis C virus neutralization by broadly neutralizing human antibodies

Children’s Hospital of Philadelphia, Philadelphia, PANathan Roy, Ph.D.*Modulation of T cell trafficking by Crk adapter proteins

Columbia University Medical Center, New York, NYYenkel Grinberg-Bleyer, Ph.D.Testing the role of NFĸκB in tumor immunity through its effect on regulatory T cells

Dana-Farber Cancer Institute, Boston, MAAdam N.R. Cartwright, Ph.D.*Systematic discovery of combination immunotherapy targets

Emory University, Atlanta, GAWilliam H. Hudson, Ph.D.*Deciphering the role of long non-coding RNAs in CD8+ T cell differentiation

Harvard Medical School, Boston, MACarmen Gerlach, Ph.D.Differentiation, function, and dynamic behavior of transitional memory cells: A novel subset of CD8+ memory T cells

Alexandra M. Greer, Ph.D.*The role of ubiquilin-1 in B cell receptor-driven lymphoma proliferation

Jason Hudak, Ph.D.Understanding microbial sensing in colorectal cancer using bioorthogonal chemistry

Chaoran Li, Ph.D.*Differentiation and accumulation of adipose-tissue regulatory T cells: Important players in the immunological control of metabolism and obesity-associated cancer

Kathleen A. McGuire, Ph.D.The role of the PD-1/PD-ligand pathway in anti-tumor immunity

Kristen E. Pauken, Ph.D.Anti-PD-1 immunotherapy: Mechanisms and impact on sustainability of CD8+ T cell responsesRobertson Foundation Fellow

Harvard T.H. Chan School of Public Health, Boston, MALior Lobel, Ph.D.*Identifying novel effectors of the gut microbiota that modulate cancer cells killing by CD8+ T cells using functional metagenomics

Icahn School of Medicine at Mount Sinai, New York, NYHelene M. Salmon, Ph.D.Contribution of the cutaneous myeloid network to melanoma response to therapyRobertson Foundation Fellow

Institut Curie, Paris, FranceYvonne K. Mburu, Ph.D.Mucosal-associated invariant T cells in anti-tumor therapyLloyd J. Old Memorial Fellow

La Jolla Institute for Allergy and Immunology, La Jolla, CAChan-Wang J. Lio, Ph.D.Role of long non-coding RNAs in the development of T cell leukemia

Christophe Pedros, Ph.D.*Control of regulatory T cell function by protein kinase C-beta (PKCκ): A novel target for cancer immunotherapy

Massachusetts Institute of Technology, Cambridge, MAAlexandra Boussommier, Ph.D.Characterizing the role of macrophages in breast cancer cell extravasation and recolonization in organ-specific 3D microfluidic models

Maria P. Frushicheva, Ph.D.ZAP-70 and Syk regulation in B cell chronic lymphocytic leukemia

Li Tang, Ph.D.T lymphocyte engineering with interleukin-2-silica nanocapsules for targeted cancer therapy

Memorial Sloan Kettering Cancer Center, New York, NYMichael C. Abt, Ph.D.Innate immune regulation of C. difficile-driven inflammation

Simone Becattini, Ph.D.*Exploring colonization resistance against Listeria monocytogenes in cancer patients

Pu Gao, Ph.D.Structural and functional studies of cytosolic DNA sensing pathwayRobertson Foundation Fellow

Jesse Green, Ph.D.Interactions of regulatory T cells with the tumor endothelium and effects on the tumor microenvironmentSamuel and Ruth Engelberg Fellow

Jing-Ping Hsin, Ph.D.The effects of cellular context on miR-155 mediated regulation of gene expressionYoung Philanthropists Council Fellow

Wei Hu, Ph.D.Tissue repair function of regulatory T cells during infection and cancer progression

Fella Tamzalit, Ph.D.The role of the centrosome in cytotoxic T cell functionLloyd J. Old Memorial Fellow

FELLA TAMZALIT, PH.D.


National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MDMichael G. Constantinides, Ph.D.Role of the microbiome in lung cancer

Vanessa K. Ridaura, Ph.D.Understanding the contributions of the skin microbiota to efficacy of melanoma immunotherapy

Ivan Vujkovic-Cvijin, Ph.D.*Identifying novel microbiome-based immunotherapeutics for melanoma

National Institute on Aging, Baltimore, MDGeoffrey Lovely, Ph.D.*Watching RAG recombinase assembly on the IgH locus and off-target assembly in live pro-B cells

National Institute of Arthritis, Musculoskeletal, and Skin Diseases, National Institutes of Health, Bethesda, MDClaudia Ouyang, Ph.D.Non-apoptotic functions of the TNF-family receptor Fas: Mechanisms and implications for autoimmunity and tumor immunotherapy

NYU Langone Medical Center, New York, NYPriya Darshinee A. Issuree, Ph.D.Roles of Runx3 in inflammatory T cells and colorectal cancer

Hao Xu, Ph.D.*Identification of the RORκt ligands, protein complexes, and targeting signals involved in Th17 cell-mediated homeostasis and pathogenesis

Mo Xu, Ph.D.Intestinal microbiota-induced Th17 responses in systemic inflammatory diseaseMargaret Dammann Eisner Fellow

Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PAMohamed Abdel Hakeem, Ph.D.*Reprogramming of exhausted T lymphocytes following cure of chronic viral infection: Implications for immunotherapy

The Rockefeller University, New York, NYRony Dahan, Ph.D. Enhancing monoclonal antibody-mediated immune responses within the tumor microenvironment

Harald Hartweger, Ph.D.*The effect of replicative stresses on the genesis of chromosome translocations

Shengdong Ke, Ph.D.RNA epigenetic HITS-CLIP: A new approach to understanding leukemia/lymphoma

Yen-Chih Wang, Ph.D.*Chemical biology of microbiota protection against gastrointestinal cancer

Stanford University School of Medicine, Stanford, CAPaola A. Betancur, Ph.D.In search of the gene regulatory circuitry responsible for the transcriptional upregulation of CD47, the “don’t eat me” signal in cancer cells

P.C. Dave P. Dingal, Ph.D.Programmable cancer recognition using a chimeric system of Notch and CRISPR

Julia Kennedy-Darling, Ph.D.Spatially defined immune cell distribution within tumor microenvironments before and after PD-L1 inhibitor treatment

Vincent Christopher Luca, Ph.D.Deconstructing the structural mechanisms of cytokine-mediated JAK activation

Roy Louis Maute, Ph.D.Characterization of the MHC/LILRB signaling axis as an immunotherapeutic target in cancer

Monica M. Olcina, Ph.D.*Innate immunity and cancer: Targeting the complement system to improve treatment response

Qian Yin, Ph.D.*Activation of endogenous anergic self-specific CD8+ T cells by polymeric nanoparticles for enhanced cancer immunotherapyLloyd J. Old Memorial Fellow

Uniformed Services University of the Health Sciences, Bethesda, MDMaria K. Traver, Ph.D.Macroautophagic control of lymphocyte activation and proliferation

University Health Network, Toronto, CanadaChristian Bassi, Ph.D.*Role of HMGB1 in breast cancer resistance to chemotherapy

Maureen Ann Cox, Ph.D.Investigation of the role of HMGB1 in asbestos-driven inflammation and mesothelioma development

University of California, Berkeley, Berkeley, CAMichele Ardolino, Ph.D.MHC-deficient tumors inactivate infiltrating natural killer cells: A new target for cancer immunotherapy

Olivia Majer, Ph.D.Dysregulated Toll-like receptor responses as an oncogenic driver

April Price, Ph.D.Expression and function of Toll-like receptors in intestinal epithelial cells

University of California, San Diego, La Jolla, CASascha H. Duttke, Ph.D.Reprogramming macrophage phenotypes during immunosurveillance and neoplastic progression

Bengt Martin Gustavsson, Ph.D.Structural basis of CXCR7 ligand binding and signalingRobertson Foundation Fellow

Hyang-Mi Lee, Ph.D.Targeting regulatory T cell-mediated regulation of IFNκy-driven anti-tumor immunity

Shabnam Shalapour, Ph.D.Development of immunosuppressive plasma cells that interfere with T cell-dependent immunogenic cancer chemotherapy

Zhenyu Zhong, Ph.D.Identification of key immune homeostatic regulators that control obesity-induced liver inflammation and disease

Yina Zhu, Ph.D.Mechanisms that underpin the sequestration of the tumor suppressor ebf1 at the nuclear lamina

University of California, San Francisco, San Francisco, CAHsin Chen, Ph.D.Mechanisms controlling lymphocyte retention in and egress from tissue

Adam H. Courtney, Ph.D.Elucidation of Lck feedback mechanismsRobertson Foundation Fellow

Brian R. Graziano, Ph.D.Using optogenetics to probe the in vivo biochemistry of cell movement

Adam J. Litterman, Ph.D.A global map of mRNA regulatory elements in CD8+ T cells

Edward W. Roberts, Ph.D.Lifespan, fate, and function of immune cells educated in primary tumors

Xiaolei Su, Ph.D.Mechanisms underlying the dynamic organization of T cell microclustersEugene V. Weissman Fellow

Adam Williamson, Ph.D.Activation of corpse engulfment to alleviate tumor-induced neurotoxicity

The University of Chicago, Chicago, ILLeticia Corrales, Ph.D.Study of the regulation of the STING/IFNκ pathway by the inflammasome/IL-1 pathway and its effect in the anti-tumor T cell response

Stefani Spranger, Ph.D.The role of tumor-intrinsic oncogene alterations in immune evasion of melanoma

University of Minnesota, Minneapolis, MNDavid Lampi Hermanson, Ph.D.Chimeric antigen receptor-directed natural killer cellular immunotherapy

Pamela C. Rosato, Ph.D.*Harnessing tissue resident memory T cells to combat solid tumors

University of Oxford, Oxford, United KingdomNathan West, Ph.D.Analysis of novel susceptibility genes in chronic intestinal inflammation and colon cancer

The University of Texas MD Anderson Cancer Center, Houston, TXKa Ho Stephen Mok, Ph.D.*Effects of anti-CTLA-4 and anti-PD-1 on memory T cell differentiation

The University of Texas Southwestern Medical Center, Dallas, TXTuo Li, Ph.D.Roles of mammalian cyclic dinucleotide signaling in cancer therapies

Xiaojun Tan, Ph.D.*Phosphoinositide regulation of STING trafficking and cancer immunity

WEI HU, PH.D.

Haidong Tang, Ph.D.Tumor-specific LIGHT targeting for cancer immunotherapy

University of Washington School of Medicine, Seattle, WAJonathan M. Clingan, Ph.D.Integration of transcriptional and translational control of the antiviral response

Elizabeth Gray, Ph.D.Functional analysis of the interferon stimulatory DNA pathway

Marc Joseph Lajoie, Ph.D.*Protein nanoparticles to elicit defined T cell response against cancer cells

University of Wisconsin-Madison, Madison, WIDavalyn R. Powell, Ph.D.The role of neutrophils and CXCL8-CXCR1/2 signaling in glioblastoma cell invasion

Vanderbilt University, Nashville, TNKaty Beckermann, M.D., Ph.D.*Metabolic barriers to T cell function and immunotherapy in renal cell carcinomaMerck Fellow

Washington University School of Medicine, St. Louis, MOJennifer K. Bando, Ph.D.Immune modulation of dormant skin tumor development and persistence

Matthew M. Gubin, Ph.D.Using genomics to identify targets of checkpoint blockade cancer treatment and to identify optimal target antigens for vaccination

Whitehead Institute for Biomedical Research, Cambridge, MAYang Eric Guo, Ph.D.Biogenesis and regulatory functions of super-enhancer RNAs in cancer cells of the immune system

Giulia Pasqual, Ph.D.In vivo tracking of B cell-T cell interactions in the germinal center

Mohammad Rashidian, Ph.D.Non-invasive imaging of immune responses for early detection of cancer and to monitor immunotherapy

Kehui Xiang, Ph.D.*Investigate the importance and mechanism of poly(A) tail length-mediated translational control in different immune cells

Yale University School of Medicine, New Haven, CTNajla Arshad, Ph.D.The effect of tumor-associated mutant calreticulin on antigen presentation and tumorigenesis

Will H. Bailis, Ph.D.Identification and characterization of immune escape mechanisms in leukemia

Guoliang Cui, Ph.D.The influence of nutrient availability in the tumor microenvironment on CD8+ T cell survival and function

Ruth A. Franklin, Ph.D.The role of macrophages in tissue homeostasis and tumor progressionDonald J. Gogel Fellow

Nicola Gagliani, Ph.D.Targeting Th17 cell plasticity to control colorectal cancer developmentDr. Keith Landesman Memorial Fellow

Noah Wolcott Palm, Ph.D.Role of helminth infections and the commensal microbiota in intestinal inflammation

Debrup Sengupta, Ph.D.Membrane trafficking events regulating cross presentation

INVESTIGATOR AWARDSFour-year bridging grants to assistant professors undertaking their first independent investigations in basic and tumor immunology, designed to provide flexibility and stability while they establish their laboratories.

Liang Zhou, M.D., Ph.D.Northwestern University, Chicago, ILMolecular mechanisms of action of Ahr in T cell differentiation and function

CLINIC AND LABORATORY INTEGRATION PROGRAM (CLIP)Two-year grants that provide catalytic support for translational laboratory studies designed to answer new scientific questions that arise in the clinic, with special focus on improving immunotherapy for cancer patients.

Austin Health/Ludwig Cancer Research, Melbourne, AustraliaJonathan S. Cebon, Ph.D., FRACPEvaluation of ROPN and SPANX as targets for antigen-specific immunotherapyWade F.B. Thompson Investigator

Brigham and Women’s Hospital/Harvard Medical School, Boston, MANiroshana Anandasabapathy, M.D., Ph.D.*Actioning a newly-defined target of peripheral tumor-immune surveillance in dendritic cells

Broad Institute of MIT and Harvard, Cambridge, MANir Hacohen, Ph.D.Unbiased single cell analysis of the lung tumor microenvironment to understand failure modes of checkpoint blockade inhibitorsWade F.B. Thompson Investigator

Cancer Research Center of Toulouse Purpan, Toulouse, FranceRoland S. Liblau, M.D., Ph.D.EVER proteins: Immune control of skin infection by beta-human papillomaviruses and skin cancer

Columbia University Medical Center, New York, NYDavid M. Owens, Ph.D.Therapeutic targeting of intrinsic T cell suppression during anti-tumor immunity

Dana-Farber Cancer Institute, Boston, MAMichael Goldberg, Ph.D.Use of CRISPR/Cas9 platform to improve function of cytotoxic T lymphocytes against melanoma

Fondazione Centro San Raffaele, Milan, ItalyMatteo Bellone, M.D.Combining adoptive T cell therapy to tumor vessel targeting and checkpoint blockade for cancer therapy

Icahn School of Medicine at Mount Sinai, New York, NYNina Bhardwaj, M.D., Ph.D.*Analysis of immune responses induced by in situ, autologous therapeutic vaccination against solid cancers with intratumoral Poly-ICLC (Hiltonol®)

Joshua Brody, M.D.Understanding a novel in situ lymphoma vaccine: Neoantigen discovery with whole exome sequencing and neoantigen-reactive T cell checkpoint molecule profiling with CyTOF

La Jolla Institute for Allergy and Immunology, La Jolla, CAStephen P. Schoenberger, Ph.D.Exome-guided neoantigen discovery and validation in head and neck squamous cell carcinoma

Leiden University Medical Center, Leiden, The NetherlandsFerry A. Ossendorp, Ph.D.Novel vaccine nanoformulations for clinical mutanome-based cancer immunotherapy

Massachusetts General Hospital, Boston, MARakesh K. Jain, Ph.D.Improving immunotherapy for metastatic breast cancer via normalization of the tumor microenvironment

Andrew D. Luster, M.D., Ph.D.*Targeting the CXCR3 chemokine system to improve anti-PD-1 immunotherapy

Mayo Clinic, Rochester, MNHaidong Dong, M.D., Ph.D.Monitoring T cell responses during anti-PD-1 therapy

Medical University of South Carolina, Charleston, SCMark P. Rubinstein, Ph.D.*Generating human tumor-reactive T cells with high levels of IL-2Rκ for adoptive T cell therapy

Memorial Sloan Kettering Cancer Center, New York, NYAlexander Y. Rudensky, Ph.D.Immunoregulatory correlates of a phase I/II study of mogamulizumab in subjects with advanced and/or metastatic solid tumorsGenentech Investigator

Northwestern University, Chicago, ILDerek A. Wainwright, Ph.D.*IDO1 in glioblastoma: Translating work from mouse to manWade F.B. Thompson Investigator

NYU Langone Medical Center, New York, NYJohn Carucci, M.D., Ph.D.Targeting the immune system to treat aggressive squamous cell carcinoma

Oregon Health & Science University, Portland, ORAmanda Lund, Ph.D.FasL-expressing lymphatic vessels in melanoma

Osaka University, Osaka, JapanHiroyoshi Nishikawa, M.D., Ph.D.Novel cancer immunotherapy targeting regulatory T cells by anti-CCR4 monoclonal antibodies

Ottawa Hospital Research Institute, Ottawa, CanadaJohn C. Bell, Ph.D.*Bioengineering an oncolytic vaccinia virus to augment the anti-tumor immune response in human cancers

QIMR Berghofer Medical Research Institute, Brisbane, AustraliaMark J. Smyth, Ph.D., FAHMSThe preclinical validation of CD96 as a checkpoint target for cancer immunotherapyWade F.B. Thompson Investigator

NIR HACOHEN, PH.D.


Saint Louis University School of Medicine, St. Louis, MORyan M. Teague, Ph.D.Defining the mechanisms of human T cell rescue by checkpoint blockade immunotherapy

Stanford University School of Medicine, Stanford, CADean W. Felsher, M.D., Ph.D.Oncogene addiction and immune activation

Holbrook E. Kohrt, M.D., Ph.D.κκ†

T cell biomarker development for effective immunotherapy for recurrent non-Hodgkin B cell lymphoma

The University of Chicago, Chicago, ILThomas F. Gajewski, M.D., Ph.D.Identification of tumor-intrinsic signaling pathways that inhibit host immune responses as potential therapeutic targets to expand the applicability of immunotherapyOliver R. Grace Investigator

The University of Melbourne, Melbourne, AustraliaJose A. Villadangos, Ph.D.Characterization and prevention of “stunning,” a cytotoxic T lymphocyte inactivating program that impairs adoptive cell therapy against cancer

UCLA Medical Center, Los Angeles, CARoger S. Lo, M.D., Ph.D.Determinants of responses to anti-PD-1/PD-L1 therapy and its combination with BRAF/MEK co-targeting in melanomaWade F.B. Thompson Investigator

Universidad Autónoma de Madrid, Madrid, SpainBruno Sainz Jr., Ph.D.Role of the innate immune system in promoting cancer stem cells

University Health Network, Toronto, CanadaTak W. Mak, Ph.D., D.Sc., F.R.S.C.*Evaluating the role of Toso-mediated inflammation in anti-tumor responses

University Hospital of Lausanne, Lausanne, SwitzerlandDaniel E. Speiser, M.D.Identification and validation of new targets for cancer immunotherapy in “exhausted” anti-cancer CD8+ T cells from mice and humans

University of California, San Francisco, San Francisco, CAMarkus Muschen, M.D., Ph.D.*Targeted hyperactivation of B cell receptor signaling to amplify therapeutic responses to CART19 treatment

University of Minnesota, Minneapolis, MNBruce R. Blazar, M.D.Lymphoid organ repair after cancer therapy for improving anti-tumor immune responses

University of Oxford, Oxford, United KingdomPaul Klenerman, M.D., Ph.D.Licensing human mucosal-associated invariant T cells to kill hepatocellular carcinomas

University of Southern California, Los Angeles, CAW. Martin Kast, Ph.D.Anti-CTLA-4 immune modulation following chemoradiation in cervical cancer patients

The University of Texas MD Anderson Cancer Center, Houston, TXMichael A. Curran, Ph.D.*Hypoxia drives tumor immune suppression and immunotherapy resistance

University of Virginia Health System, Charlottesville, VACraig L. Slingluff Jr., M.D.Retention integrins: Induction and function on cancer-reactive T lymphocytesWade F.B. Thompson Investigator

Vanderbilt University, Nashville, TNJeffrey C. Rathmell, Ph.D.Metabolic immunosuppression of T cells in clear cell renal cell carcinoma and anti-PD-1 therapyWade F.B. Thompson Investigator

Walter and Eliza Hall Institute of Medical Research, Melbourne, AustraliaNicholas David Huntington, Ph.D.*Development of a checkpoint inhibitor that targets the intracellular protein CIS to enhance natural killer cell anti-tumor immunity

Washington University School of Medicine, St. Louis, MOGavin P. Dunn, M.D., Ph.D.*Monitoring the anti-tumor immune response in glioblastoma patients treated with a personalized neoepitope vaccine

Weill Cornell Medicine, New York, NYJuan R. Cubillos-Ruiz, Ph.D.*Targeting LPA sensors in the tumor microenvironment to enhance ovarian cancer immunotherapiesWade F.B. Thompson Investigator

Yale School of Medicine, New Haven, CTSusan M. Kaech, Ph.D.Enhancing immunotherapy-based cancer treatments through CD40-dependent immunomodulation of the tumor microenvironmentWade F.B. Thompson Investigator

COORDINATED CANCER INITIATIVESFunding for research in specified cancer areas deemed able to provide clinically relevant insights and discoveries with the potential to accelerate development of cancer immunotherapies.

Centre de Lutte Contre Le Cancer Nantes-Atlantique, Nantes-Saint Herblain, FranceDanila Valmori, Ph.D.Vaccination strategies for the treatment of epithelial ovarian cancer

Icahn School of Medicine at Mount Sinai, New York, NYHearn Jay Cho, M.D., Ph.D.Vaccine immunotherapy program in multiple myeloma

Institut Gustave Roussy, Villejuif, FranceMaha Ayyoub, Ph.D.Role of the gut microbiota in the ontogeny and homeostasis of regulatory CD4+ T cells and in their alteration along immune responses to ovarian cancer

CLINICAL ACCELERATORThe Clinical Accelerator brings together the best capabilities of the world’s leading academic researchers, drug companies, and a unique nonprofit venture fund to kick-start the development of powerful new treatments for cancer patients. To view a list of all current sites and lead investigators, go to page 53.

CLINICAL STRATEGY TEAM GRANTS

Team Leads: Nina Bhardwaj, M.D., Ph.D., and Sacha Gnjatic, Ph.D.Investigators: Eric Schadt, Ph.D., Rachel Sabado, Ph.D., Matthew D. Galsky, M.D., Icahn School of Medicine at Mount Sinai, New York, NYThe mutation-derived tumor landscape of advanced bladder cancer: A platform to optimize cancer immunotherapy

Team Lead: John C. Herr, Ph.D.κ† κUniversity of Virginia Health System, Charlottesville, VAInvestigators: Victor Engelhard, Ph.D., Craig Slingluff, M.D., and Timothy Bullock, Ph.D., and Mark Kester, Ph.D., University of Virginia Health System, Charlottesvillel, VA; Jamal Zweit, Ph.D., Virginia Commonwealth University, Richmond, VAImmunotherapeutic targeting cell surface neoantigen SAS1B (Ovastacin, ASTL)

Team Leads: Hideho Okada, M.D., Ph.D., and Lawrence Fong, M.D., University of California, San Francisco, San Francisco, CAInvestigators: Robert P. Edwards, M.D., Pawel Kalinski, Ph.D., University of Pittsburgh School of Medicine, Pittsburgh, PA; Kunle Odunsi, M.D., Ph.D., Roswell Park Cancer Institute, Buffalo, NYEnhancing T cell homing to solid cancers by stimulating proper chemokines

Team Lead: Andrew Sikora, M.D., Ph.D., Baylor College of Medicine, Houston, TXInvestigators: Sacha Gnjatic, Ph.D., Icahn School of Medicine at Mount Sinai, New York, NY; Christine Chung, M.D., Moffitt Cancer Center, Tampa, FL; Nham Tran, Ph.D., University of Technology, Sydney, Australia; Cornelis J.M. Melief, M.D., Ph.D., Leiden University, Leiden, The NetherlandsTargeting the tumor immune microenvironment to enhance immune-stimulating effects of chemoradiotherapy

Team Lead: Mark J. Smyth, Ph.D., FAHMS, QIMR Berghofer Medical Research Institute, Brisbane, AustraliaInvestigators: Scott J. Antonia, M.D., Ph.D., Moffitt Cancer Center, Tampa, FL; Georgina V. Long, Ph.D., M.B.B.S., and Richard Scolyer, M.B.B.S., M.D., Melanoma Institute of Australia and University of Sydney, Sydney, Australia; John Stagg, Ph.D., University of Montréal, Montréal, CanadaTargeting adenosine in the tumor microenvironment

Team Leads: Hassane M. Zarour, M.D., and John M. Kirkwood, M.D. Investigators: James J. Lee, M.D., Mark A. Socinsky, M.D., Adam M. Brufsky, M.D., Ph.D., University of Pittsburgh School of Medicine, Pittsburgh, PA; Alan J. Korman, Ph.D., Bristol-Myers Squibb, Redwood City, CATargeting multiple inhibitory receptors in cancer patients

BRUCE R. BLAZAR, M.D.


κ†Deceased

Team Lead: Lei Zheng, M.D., Ph.D., Investigators: Elizabeth Jaffee, M.D., Eric Lutz, Ph.D., Todd Armstron, Ph.D., Johns Hopkins University School of Medicine, Baltimore, MDTipping the balance in the tumor microenvironment as a next generation platform for pancreatic cancer immunotherapy

CLINICAL TRIALS FUNDED

A first-in-human single ascending dose study of TRX518 in subjects with unresectable stage III or stage IV malignant melanoma or other solid tumor malignancies• Henry Koon, M.D., University

Hospitals, Cleveland, OH• Dale Shepard, M.D., Ph.D.,

Cleveland Clinic, Cleveland, OH• Jedd D. Wolchok, M.D., Ph.D., and

Margaret Callahan, M.D., Ph.D., Memorial Sloan Kettering Cancer Center, New York, NY

An open label, phase I study of a neoantigen vaccine (TESLA-001), with a checkpoint inhibitor, in patients with metastatic cancer*• Nina Bhardwaj, M.D., Ph.D., Icahn

School of Medicine at Mount Sinai, New York, NY

• Gavin Dunn, M.D., Ph.D., Washington University School of Medicine, St. Louis, MO

A phase I study of NY-ESO-1 vaccine in combination with ipilimumab in patients with unresectable or metastatic melanoma, for whom treatment with ipilimumab is indicated• Jonathan S. Cebon, Ph.D., FRACP,

Austin Health/Ludwig Cancer Research, Melbourne, Australia

• Craig E. Devoe, M.D., North Shore LIJ, North Shore University Hospital, Manhasset, NY

• Philip Friedlander, M.D., Icahn School of Medicine at Mount Sinai, New York, NY

• Michael A. Postow, M.D., Memorial Sloan Kettering Cancer Center, New York, NY

• Craig L. Slingluff Jr., M.D., University of Virginia Health System, Charlottesville, VA

• Hussein Tawbi, M.D., Ph.D., University of Pittsburgh Cancer Institute, Pittsburgh, PA

Phase I study to assess safety and tolerability of tremelimumab and durvalumab, administered with high dose chemotherapy and autologous stem cell transplant *• Hearn Jay Cho, M.D., Ph.D.,

Icahn School of Medicine at Mount Sinai, New York, NY

• Alexander M. Lesokhin, M.D., Memorial Sloan Kettering Cancer Center, New York, NY

A phase I study to evaluate the safety and tolerability of anti-PD-L1, durvalumab, in combination with tremelimumab in subjects with advanced solid tumors• Kunle Odunsi, M.D., Ph.D., Anna-

Maria Kellen Clinical Investigator, Roswell Park Cancer Institute, Buffalo, NY

• Patrick Ott, M.D., Ph.D., Dana-Farber Cancer Institute, Boston, MA

• Jedd D. Wolchok, M.D., Ph.D., and Margaret Callahan, M.D., Ph.D., Memorial Sloan Kettering Cancer Center, New York, NY

A phase I/II dose escalation study with expansion cohorts to investigate the safety, biologic and anti-tumor activity of ONCOS-102 in combination with durvalumab in subjects with advanced peritoneal malignancies *• Dmitriy Zamarin, M.D., Ph.D.,

Memorial Sloan Kettering Cancer Center, New York, NY

A study of ALK inhibitor, ensartinib, and anti-PD-L1, durvalumab, in subjects with ALK-rearranged non-small cell lung cancer/a phase I/II study of combination immunotherapy and mRNA vaccine in subjects with non-small-cell lung cancer (NSCLC)• Leena Gandhi, M.D., Ph.D., NYU

Langone Medical Center, New York, NY

A phase I/II study of in situ vaccination with tremelimumab and IV durvalumab plus Poly-ICLC in subjects with advanced, measurable, biopsy-accessible cancers *• Nina Bhardwaj, M.D., Ph.D., Icahn


• Craig L. Slingluff Jr., M.D., University of Virginia Health System, Charlottesville, VA

A phase II study to evaluate the clinical efficacy and safety of standards of care in combination with checkpoint blockade in patients with glioblastoma*• David A. Reardon, M.D.,

Dana-Farber Cancer Institute, Boston, MA

Phase I/II study of chemo-immunotherapy with Toll-like receptor 8 agonist motolimod and checkpoint blockade in subjects with recurrent, platinum-resistant ovarian cancer for whom pegylated liposomal doxorubicin is indicated• George Coukos, M.D., Ph.D.,

University Hospital of Lausanne, Lausanne, Switzerland

TRIALS SUPPORTED WITH REAGENTS

A multi-peptide vaccine plus Toll-like receptor agonists in melanoma patients, with evaluation of the injection site microenvironment for resected stage IIB-IV• Craig L. Slingluff Jr., M.D.,

University of Virginia Health System, Charlottesville, VA

A phase I open label, multicenter, multi-ascending dose trial evaluating the safety, tolerability, and immunogenicity of intramuscular recombinant NY-ESO-1 protein with GLA-SE adjuvant in patients with unresectable or metastatic cancer expressing NY-ESO-1• Immune Design, Seattle, WA

A phase I study of cancer vaccine CHP-NY-ESO-1 in combination with Poly-ICLC in patients with esophageal cancer or malignant melanoma expressing NY-ESO-1• Hiroshi Shiku, M.D., and Shinichi

Kageyama, M.D., Mie University School of Medicine, Mie, Japan

A phase I study of concomitant WT1 analog peptide and NY-ESO-1• David O’Malley, M.D., The Ohio

State University Wexner Medical Center, Columbus, OH

• Paul Sabbatini, M.D., Memorial Sloan Kettering Cancer Center, New York, NY

A phase I study of vaccination with NY-ESO-1 protein mixed with Poly-ICLC, OK-432 (Picibanil®), and ISA-51 (Montanide®) in patients with advanced cancers expressing NY-ESO-1• Yuichiro Doki, Ph.D., and Hisashi

Wada, M.D., Ph.D., Osaka University, Osaka, Japan

A phase IA/IB study of vaccination with NY-ESO-1 protein, Poly-ICLC, and mogamulizumab in patients with adult T cell leukemia/lymphoma expressing NY-ESO-1• Yuzuru Kanakura, Ph.D., and

Hiroyoshi Nishikawa, M.D., Ph.D., Osaka University, Osaka, Japan

A phase II open label randomized study of Poly-ICLC-matured dendritic cells as an adjuvant for NY-ESO-1 and MELANA/MART-1 peptide vaccination compared to Montanide ISA-51 in patients with melanoma• Nina Bhardwaj, M.D., Ph.D., Icahn


A pilot study of a novel multimodality immuno-chemotherapy platform for patients with advanced cutaneous T cell lymphoma• Catherine M. Diefenbach, M.D.,

NYU Langone Medical Center, New York, NY

A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus Poly-ICLC in stage IB-IIIA breast cancer• Patrick M. Dillon, M.D., University

of Virginia Health System, Charlottesville, VA

A preclinical mouse vaccination experiment to compare the effectiveness of Poly-ICLC to that of the more common QS-21• Samuel Danishefsky, Ph.D.,

Memorial Sloan Kettering Cancer Center, New York, NY

A trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus novel adjuvant combinations• Craig L. Slingluff Jr., M.D.,


Evaluation of safety and immunogenicity of a multi-phosphapeptide vaccine plus Poly-ICLC in participants with melanoma• Victor H. Engelhard, Ph.D.,

and Craig L. Slingluff Jr., M.D., University of Virginia Health System, Charlottesville, VA

General research purposes (Poly-ICLC)• Fathia Mami-Chouaib, Ph.D.,

Institut Gustave Roussy, Villejuif, France

General research purposes (Poly-ICLC)• OncoPep, Inc.,

North Andover, MA

Phase I study of NY-ESO-1 protein + Poly-ICLC +/- Montanide® ISA-51 VG vaccine in patients with advanced malignant melanoma• Nina Bhardwaj, M.D., Ph.D., Icahn


LEENA GANDHI, M.D.,PH.D.


Phase I/II trial of a long peptide vaccine (LPV8) + Toll-like receptor agonists for resected stage IIB-IV• Craig L. Slingluff Jr., M.D.,


Role of Toll-like receptor 3 in macrophage-mediated programmed cell removal of tumor cells• Irving Weissman, M.D., Stanford

University School of Medicine, Stanford, CA

Safety and immunogenicity of vaccination with XAGE1b long peptides combined with Poly-ICLC in patients with stage III/IV pulmonary adenocarcinoma• Christian Taube, M.D., and

Maarten L. Zandvliet, Ph.D., Leiden University Medical Center, Leiden, The Netherlands

CORRELATIVE AND LABORATORY STUDIES

Maha Ayyoub, Ph.D., Institut Gustave Roussy, Villejuif, FranceEarly-phase NY-ESO-1 clinical trials in patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma and monitoring of tumor-specific immune responses

Nina Bhardwaj, M.D., Ph.D., Icahn School of Medicine at Mount Sinai, New York, NY, and Anna C. Pavlick, D.O., NYU Langone Medical Center, New York, NYPhase II study of CTLA-4 blockade and low dose cyclophosphamide in patients with advanced malignant melanoma after failure of at least one prior therapy

Sacha Gnjatic, Ph.D., Icahn School of Medicine at Mount Sinai, New York, NYImmunological monitoring for Cancer Vaccine Collaborative trials

Elke Jäger, M.D., Krankenhaus Nordwest, Frankfurt, GermanyCore support for NY-ESO-1 clinical trials

Daniel E. Speiser, M.D., University Hospital of Lausanne, Lausanne, SwitzerlandVaccination of melanoma patients (stage II-IV) with ImmuFact IMP321, tumor antigenic peptides, and Montanide

Danila Valmori, Ph.D., Centre de Lutte Contre Le Cancer Nantes-Atlantique, Nantes-Saint Herblain, FranceEarly-phase NY-ESO-1 clinical trials in patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma and monitoring of tumor-specific immune responses

REAGENT MANUFACTURE

Production of NY-ESO-1 overlapping peptides for use in a variety of trialsPolyPeptide Laboratories San Diego, San Diego, CA

Poly-ICLC stability testingOncovir, Inc., Washington, DC

LEVERAGED GRANTSSpecial partnerships to explore novel preclinical and clinical studies in high-priority research areas.

James P. Allison, Ph.D., The University of Texas MD Anderson Cancer Center, Houston, TX, and Antoni Ribas, M.D., Ph.D., UCLA Medical Center, Los Angeles, CACancer Immunology Translational Research Dream Team: Immunologic checkpoint blockade and adoptive T cell transfer in cancer therapyIn partnership with the Entertainment Industry Foundation/Stand Up To Cancer

Carl H. June, M.D., and Gregory L. Beatty, M.D., Ph.D.Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PAMesothelin-specific chimeric antigen receptor (CAR) T cell therapy for pancreatic cancerIn partnership with the Lustgarten Foundation

DESIGNATED GRANTSGrants to support research projects and public education and awareness initiatives for which, in most cases, donors have specifically raised funds.

American Association for Cancer Research*Collaboration on Cancer Immunology Research

Timothy N.J. Bullock, Ph.D.University of Virginia Health System, Charlottesville, VAEnhancing immune therapy for brain metastases with focused ultrasoundIn partnership with the Focused Ultrasound Foundation

George Klein, M.D., D.Sc.*Karolinska Institutet, Stockholm, SwedenStudies on Epstein-Barr virus oncogenes and tumor suppressor genes, tumor immunology, and inhibition of tumor cell growth by stroma cellsIn partnership with the Concern Foundation

Malcolm A.S. Moore, D.Phil.*Memorial Sloan Kettering Cancer Center, New York, NYThe study of hematopoietic stem cells and progenitor populations in normal and cancer cellsGar Reichman Laboratory

ANNUAL AWARDSIn addition to providing financial support to researchers and investigators, CRI also honors scientists and community leaders with achievement awards.

WILLIAM B. COLEY AWARD FOR DISTINGUISHED RESEARCH IN BASIC AND TUMOR IMMUNOLOGYAnnual prize given to one or more scientists whose discoveries in the fields of immunology or tumor immunology contribute to the advancement of immune system-based therapies for cancer.

Glenn Dranoff, M.D.*Novartis Institute for BioMedical Research, Cambridge, MA

Alexander Y. Rudensky, Ph.D.*Memorial Sloan Kettering Cancer Center, Ludwig Cancer Research, New York, NY

FREDERICK W. ALT AWARD FOR NEW DISCOVERIES IN IMMUNOLOGYPrize honoring a former postdoctoral fellow in recognition of outstanding success in academia or industry for research that may have a potentially major impact on immunology.

Nina Bhardwaj, M.D., Ph.D.*Icahn School of Medicine at Mount Sinai, New York, NY

CARL H. JUNE, M.D.

AACR-CRI LLOYD J. OLD AWARD IN CANCER IMMUNOLOGYAward recognizes an active scientist whose outstanding and innovative research in cancer immunology has had a far-reaching impact on the cancer field.

Ronald Levy, M.D.*Stanford University, Stanford, CAIn partnership with the American Association for Cancer Research

OLIVER R. GRACE AWARD FOR DISTINGUISHED SERVICE IN ADVANCING CANCER RESEARCHAnnual prize that recognizes the contributions of dedicated laypersons or organizations whose leadership has had a significant impact on cancer research.

Kenneth C. Frazier*Chairman and CEO, Merck & Co.

Lauren S. Veronis*Trustee, Cancer Research Institute, and Former President, Irvington Institute for Immunological Research


FU

ND

RA

ISIN

G

Everything the Cancer Research Institute does to keep the momentum of scientific progress moving forward would not be possible without generous support from individuals,

foundations, and corporations who are as passionate as we are to see an end to cancer as we know it. The outpouring of generosity has given us another record-breaking year of fundraising. Together, contributions to CRI from donors totaled $42.1 million last year—a signal of donor trust in CRI that will allow us to fund more research that translates into more lives saved.

From the thousands of individuals who make personal donations, to the passionate Team CRI members who plan fundraising events or participate in major endurance events around the country, to the families who donate yearly in memory of a loved one, and our trustees who give generously of both their time and money, no gift to CRI goes unappreciated. These contributions continue to make a difference in the life of the organization and the impact of its work.

$42.1MILLION FROM CONTRIBUTIONS AND SPECIAL EVENTS

260+TEAM CRIFUNDRAISINGEVENTS

Powering Progress to Save Lives

When I ask my friends, family, and coworkers to support my fundraising efforts for CRI, I do so knowing that any gift, in any amount, is going to be used wisely, and ultimately will help us stop this terrible disease.

Priyanka SewhaniChair, CRI Young Philanthropists CouncilTop Individual Fundraiser, 2016 Answer to Cancer Cycling Event


To read stories of CRI donors, visit cancerresearch.org/supporters

CRI CEO AND DIRECTOR OF SCIENTIFIC AFFAIRS JILL O’DONNELL-TORMEY WITH FORMER REVLON CEO LORENZO DELPANI AND REVLON AMBASSADORS OLIVIA WILDE AND HALLE BERRY; NBC TODAY SHOW HOST MATT LAUER AT THE THROUGH THE KITCHEN PARTY; SEVEN-YEAR-OLD SAGE DREW PICTURES OF ANIMALS TO RAISE FUNDS FOR CRI; TEAM CRI RUNNERS IN 2016 UNITED AIRLINES NEW YORK HALF MARATHON; ST. LOUIS-BASED T-SHIRT COMPANY, TEE TURTLE, RAISED MORE THAN $54,000

DO

NO

RS

The Cancer Research Institute’s ability to advance important science and facilitate the development of immunotherapies for all types of cancer is made possible through the generous support of

our donors. Acknowledgments listed here reflect contributions of $1,000 and more made to CRI between July 1, 2015, and June 30, 2016.

$1,000,000+ Bristol-Myers Squibb Anna-Maria and Stephen Kellen

Foundation MedImmune, Inc. The Thompson Family

Foundation

$500,000 - $999,999 The Hearst Foundations, Inc. Merck Multiple Myeloma Research

Foundation, Inc.

$100,000 - $499,999 Merle S. Cahn Foundation Clinton Global Initiative Estate of Prudence Cometa Concern Foundation Rose Marie Craig Trust Mr. and Mrs. Maurice J. Cunniffe Fight Colorectal Cancer Genentech GlaxoSmithKline Oliver R. Grace

Charitable Foundation Estate of Inez G. Koch The Ambrose Monell Foundation Revlon Mr. and Mrs. Brian Riano Estate of Gertrude Schelling Betsy and Paul Shiverick / Shelter Hill Foundation The Estate of John Strang The Wildflower Foundation, Inc.

$50,000-$99,999 Amgen AstraZeneca Pharmaceuticals LP Estate of Stuart Sidney Bernard Mr. and Mrs. Edgar R. Berner Bloomberg Philanthropies Estate of Frederick J. Brand

Supporting the Cause

Jennifer L. Brorsen and Richard M. DeMartini

Ann and Geoffrey O. Coley Estate of Salvatore Corsaro Debevoise & Plimpton LLP Estate of Ruth Engelberg Mr. and Mrs. Sean P. Fahey Georgia and Don Gogel Janet Greenfield

and Peter L. Bloom Marlene Hess and James Zirin Marion Esser Kaufmann

Foundation F.M. Kirby Foundation, Inc. Mr. and Mrs. Kenneth G. Langone Mr. and Mrs. Alexander P. Lynch The Honorable Colleen

McMahon and Frank V. Sica Joan Meltesen Unitrust Andy and Tom Mendell Orinoco Foundation Mr. and Mrs. Andrew M. Paul Linda C. Pinkus Fund of

the Community Foundation of New Jersey

Regeneron Pharmaceuticals, Inc. Johanna and Lief D. Rosenblatt Jeanne and Herb Siegel Jane and James Stern Sharzad and Michael Targoff Tee Turtle LLC Mr. and Mrs. Andrew K. Tsai Diane and Tom Tuft Ueberroth Family Foundation Lauren and John Veronis Jim Weiss, W2O Group Peter Zhou

$25,000-$49,999 Agenus, Inc. Baird The Jeanne E. and Jacob A.

Barkey Memorial Fund CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT 33

Beazley Group Kenneth N. Borofsky Estate of Raymond V. Byrne Richard E. Capri Foundation Celldex Therapeutics, Inc. Clayton, Dubilier & Rice LLC Frederic R. Coudert Foundation Leslie and Bob Dahl Oliver S. and Jennie R. Donaldson Charitable Trust The John and Jenny Eckerson Family Foundation Albert Nathan Eisenberg

Charitable Foundation Eli Lilly & Company The John and Christine

Fitzgibbons Foundation Sophie Garafola Goldman Sachs Group, Inc. Herman B. Golub Charitable Trust Green Charitable Foundation, Inc. Mary Gurster

Hagedorn Fund Jeffrey Hammerbacher Leonard Lauder Mr. and Mrs. Ronald S. Lauder Miltenyi Biotec, Inc. Estate of Jean Marie Newcomer Anna Oschwald Trust Perri Peltz and Eric Ruttenberg David M. Polen Retirement Plan

Proceeds Trust Bruce C. Ratner Mr. and Mrs. Michael A. Roe Edmond J. Safra Foundation Edith M. Schweckendieck Trusts Elena and Scott Shleifer Wachtell, Lipton, Rosen & Katz The Wasily Family

Foundation, Inc.

$10,000-$24,999 James P. Allison, Ph.D. Dr. Eva Andersson-Dubin

and Mr. Glenn Dubin

Anonymous Ronit and Marc Arginteanu Fund Yacov Arnopolin Alixandra Englund Audiberti Rose M. Badgeley Residuary Charitable Trust Judy and Ron Baron Charles N. Bartunek Bonbright Family

Foundation Trust Mr. and Mrs. Charles Bronfman Jeffrey A. Burki Mr. and Mrs. Russell L. Carson James M. Citrin Corning Incorporated Karen and Matthew Crews Mr. and Mrs. Glenn J. DeSimone Domain Associates, LLC Dr. and Mrs. Ronald I. Dozoretz Thea Duell and Peter Cook Thomas English Fribourg Family Foundation

WHITE OUT THE PLAZA EVENT


Estate of James Gagliano Mr. and Mrs. Victor Ganzi Ambassador Charles A. Gargano Gratis Foundation Joyce Green Family Foundation Heidi Greene and Michael Kluger Seth Grossman GuideVine Technologies The Marc Haas Foundation Mr. and Mrs. Talbot Hamilton Shirley & Burt Harris

Family Foundation Hempleman Family

Charitable Giving Fund The Hurlbert Family Foundation The Karev Foundation Joel J. Kassimir Megan V. Kearney

and Paul Enright LabAnswer and Its Employees The Max, Malie, Dr. Leonard,

and Bernice Laub FamilyFoundation

Mr. and Mrs. Matt Lauer The Ralph and Ricky Lauren

Family Foundation Dalia and Larry Leeds Estate of Mildred Leiffer Florence & Edgar Leslie

Charitable Trust Estate of Francis R. Linden Gordon J. Linden Loncar Investments LLC The Longhill Charitable

Foundation Inc Loon Point Foundation Larry L. Luing Family Foundation Albert Marino Nancy L. Mauro

Mr. and Mrs. Wesley McDonald Estate of Sharon H. McGowan Emil and Toby Meshberg Family Foundation Inc. Morgan Stanley & Co. Mr. and Mrs. Richard P. Morgenstern Mr. and Mrs. Jacques C. Nordeman North State Cancer League Royce E. Oliver Jr. Pace, Inc. PDT, Inc. Mr. and Mrs. Jeffrey M. Peek Harlan Peltz The Research Foundation of CUNY Carlos Rodriguez-Pastor The Edward John and Patricia Rosenwald Foundation Hillary and Wilbur Ross Schaumburg Professional

Firefighters BE Adolph & Ruth Schnurmacher Foundation, Inc. The Estate of Louise S. SchoenkeLori Squire Mr. and Mrs. Leonard N. Stern Walter and Louise Sutcliffe

Foundation Michael Steven Swell Liz Whitney Tippett Foundation, Inc. Estate of Zelda M. Uthe Mr. and Mrs. Ronald G. Weiner,

Perelson Weiner LLP Wells Fargo Robert D. Welsh Lally Graham Weymouth and

Joseph M. Cohen Whiting Foundation The Wiggins Foundation, Inc.

$5,000-$9,999AbbVie Inc.Gino Adamo’s St. Joseph

Dinner DanceAlexander and Johannes

Charitable FundJane B. AllenCalifornia Fund of the

Hugh J. Andersen FoundationChristopher AnkoviakAnonymous (6)Backman Research FoundationC.R. Bard FoundationBasin HoldingsMercedes T. Bass

Charitable CorporationCurtis BerganCathie Black and Tom HarveyMr. and Mrs. James C. BlairFranci J. Blassberg and

Joseph L. Rice IIIBorderland 2 on TwitchThe Henry W. Bull FoundationPat and Gil CaffrayKevin CookMr. and Mrs. Richard CoreyMr. and Mrs. Skip CressmanDanem FoundationEisnerAmper LLPFrank M. Ewing Foundation, Inc.Mr. and Mrs. Carlos A. FerrerTom FrancoSam FriedmanSteven M. GalbraithMr. and Mrs. Nathan GantcherTerrell GatesCheryl & Edward S. Gordon

Foundation

J. Ira and Nicki Harris Family Foundation

Rochelle and David A. HirschFoundation, Inc.

Mr. and Mrs. William D. HobbsInnovate International Intelligence

& Integration, LLCInovio PharmaceuticalsMr. and Mrs. George KaufmanRichard and Suzanne Kayne

Charitable FundRachel Rutherford Englund KnappMr. and Mrs. David H. KochDr. Donald KuspitCharles and Margaret Levin

Family FoundationMichael LittAudra M. LiuW. Bruce LunsfordD. Scott MackesyMr. and Mrs. Christopher L.

MarhoferEvan McDonald-StewartGuillaume MearJoseph MitolaMitsubishi UFJ Securities (USA), Inc.Dr. and Mrs. Malcolm MooreNandanson Charitable FoundationNewgen Strategies

and Solutions, LLCNewLink Genetics CorporationNorthfield BankMorris W. OffitParkell, Inc.Chris ParryVickie and Rahn PitzerPluralsightVerne C. PowellQuerrey Simpson

Charitable FoundationThe Raether 1985 Charitable TrustGeoffrey S. RakerKristin and Michael Reed

Family Foundation, Inc.Reed-Lane, Inc.Mr. and Mrs. Karl RoessnerDaryl and Steven Roth FoundationJami RubinPeter Craig RussellSeaman Family FoundationKevin W. SharerMichael Charles SharpMr. and Mrs. Paul H. SherryMr. and Mrs. Brian Sir

Mr. and Mrs. Craig SmithGeraldine and Ernest SmithSocket Telecom LLCMichael SorensenStainman Family FoundationDr. David StauntonMr. and Mrs. Allan SternMr. and Mrs. Douglas StoneSharon and Tom TelesThe Thom Family Foundation, Inc.Elizabeth and Jim TinsmanVenables, Bell & Partners LLCPaul H. Volpe Revocable TrustJeff WebbHarriet and Ronald WeintraubMr. and Mrs. James C. Zelter $1,000-$4,99924-7 Auto Transport, Inc.Qasim AbbasRichard AbbeyDebbie H. AbbottKedar AbhyankarAbbey and Richard AbornJohnson AbrahamAccentureMr. and Mrs. Lawrence N. AckleyJohn E. AdamsADI Meetings & EventsMr. and Mrs. Anthony AellenAeroDyn Wind Tunnel LLCFrank AlbericoJohn AlexanderPatrick AllareLouise AllchinAllianceDataAllied World Assurance Company

Jennifer AlmeidaAudrie and Todd AlsdorfDr. Amy AlspachAmerican Hospice FoundationAmerican Life GroupRichard AmmermanTom AmpeliotisMr. and Mrs. Dale P. AndersonRobert G. AndrewsAnonymous (35)Imane AnysFadi ArbidAriel Capital Management, LLCGaro H. Armen, Ph.D.Henry ArnholdJan AronsonASA ResearchMr. and Mrs. Joseph Azara Jr.Michael BabiarzKatherine and Mark BabinDarius BabusisKevin BacaFrederico BandiniMr. and Mrs. Joseph BankCharles B. BanksBrett BarganzDavid BaronThe Barrington Foundation, Inc.Pamela S. Barry, Ph.D., and Thomas W. Schneider, Ph.D.Mary and Thomas BartlettStephen J. BastoneMr. and Mrs. Neil BayerRobbie and Ted BeatyBeckman-Matsui

Family FoundationMr. and Mrs. Everett A. Bell

I am so grateful for all the folks that are fundraising and actively raising awareness with the Cancer Research Institute, who are helping patients like me who, after failing all other clinical trials, are looking for the next option.

Ariella Hodgkin lymphoma survivor treated with immunotherapy

THE DONNY G MEMORIAL GOLF TOURNAMENT


Bell Forest ProductsKathleen BelstenJoanne BenedictMr. and Mrs. Jonathon BerezinskiThe Berkowitz Family FoundationEdward BermasAdler BernardMr. and Mrs. Mark BerryScott M. BesawBethel Park School DistrictMr. and Mrs. Larry D. BillenGino V. BirbigliaThe Birchwood Country Club

IncorporatedMr. and Mrs. James W. Bishop Jr.Sharon and David BishopCarol BiusoBurke BlackMr. and Mrs. James A. BlockKelly and Steve BloomTheodore BlumenthalStuart H. BohartBarnabas BoonTed J. Boulanger TrustSylvia BowerLisa and David BoyleBP Foundation, Inc.Brandt & Hochman

Literary Agents, Inc.Marie Brenner and

Ernest PomerantzSamuel BretheimPatrick BrettBridges Family Charitable FundChristian W. BrinkmanLouis J. BriskmanJess BrownJudith S. and David B. BrownWilliam E. BrownMr. and Mrs. Mike BrzozowskiCarla J. BuckKathy D. BuehneMr. and Mrs. Gregory A. BuhlChris BurellMr. and Mrs. Tom BurmanCaesars Enterprise Services LLCMr. and Mrs. John CalicchioThe Campbell FamilyEileen Campbell

and Struan RobertsonMr. and Mrs. Rohn CampbellAntonio CampoJennifer Cardettino

and Andrew Hite

Virginia and Edward Caress Family Fund

Harold CarrMr. and Mrs. Robert A. CarterMr. and Mrs. Patrick CassidyThe Cayuga FoundationDr. Jacob M. ChackoDr. David R. ChapmanPatrick ChapmanRory ChappleKevin CharltonJenchi ChenKurtis CiceroEleanor Clain-StefanelliMr. and Mrs. Daniel K. ClarkSuzette ClaytonClean Slate MediaMr. and Mrs. Rodney CobbSteve CohenMichael J. CohnJames CoilJean P. ColacoMichael CominottoAnna CondoKevin ConwayBob CooperCeCe CordMr. and Mrs. Ronald CoutureMr. and Mrs. James R. CoyleCPAs 4 MDs, PACraigslist Charitable FundWilliam S. CredleMr. and Mrs. Christopher J. CreedD. Kirk CromerCrossler Middle SchoolZoe CruzCSX TransportationLori Cuisinier

and Anthony HobermanThe Randi and Roger

Cunningham Charitable FundMr. and Mrs. John R. Curtis Jr.Cushman Family FoundationThe Wayne and Nicole Cypen

Philanthropic Fund at the Miami Foundation

Thomas DalyMr. and Mrs. Barrie M. DamsonMr. and Mrs. Timothy DanaherMunir DauhajreMr. and Mrs. Jason DavenportGregory J. DaviesAshley N. DavisMr. and Mrs. Gary Davis

Mr. and Mrs. Roberto de GuardiolaNathalie and Charles de

GunzbergChristina De Mi RandaDedicated Defined Benefit

Services, LLCDella Calce Private Foundation, Inc.Emily and Rutger deQuayMr. and Mrs. Paul DertienDevonwood FoundationSam C. DickerMr. and Mrs. Andrew DickmanMr. and Mrs. Michael D. DillonKatherine DinesMr. and Mrs. John H. DobbinsMr. and Mrs. Dennis R. DodsonMr. and Mrs. Scott A. DondershineMichael DonohueScott DresslerMarie DudickDeborah DumaineNancy P. DurrMelinda EdelcupChristopher S. EdwardsMr. and Mrs. Stephen C. ElkinDavid EmanuelRalph Enderby Survivors TrustHiroaki EtoE. Joseph Evans Charitable TrustDr. and Mrs. Anthony B. EvninMr. and Mrs. Benjamin FalchukMr. and Mrs. Thomas E. FalgoutMadeleine FarragherStephen P. FarrarDean FearingAndrew FernandezLouise Egdorf FescineFinneran Family FoundationMr. and Mrs. Winston O. FitzhughJohn A. FloodDaniel FloresThomas FoleyJoshua FordFort Myers Broadcasting Co.Fortress Investment Group LLCForYourParty.comRussell FrandinEthan Frey - Brookshire RealtyBarry FriedbergScott FriedmanJonathan GainsleyCarolyn D. GaitesNeil GallagherDanielle and David Ganek

Deborah GarciaJohn A. GardnerLinda M. GaseThe Estate of Fritz GautschiGE FoundationGenomic Health, Inc.Mohsen GhaneianMarlene GillisKenneth GiuriceoMr. and Mrs. David GlendinningMr. and Mrs. Kenneth H. GlobusJoseph GodleyVictoria L. GoldbergMax Goldenberg FoundationAndrew GoldmanEllen M. Golub

Charitable FoundationThe Goodman-Lipman Family

Foundation Inc.Dan L. GoodwinGotham ColorKen GottesmanMr. and Mrs. Jason GottliebWalter J. GrandfieldJillian GriffithsAline and Richard GrimesKathryn GrossmanGuardians of CridheMr. and Mrs. William M. GutowitzHackerAgencyEdward E. Haddock, Jr.

Family FoundationJoshua D. HallTroy HaltermanMargaret H. HamachekThe Hampton Landing Co., LLCAdam D. HandwerkerMr. and Mrs. Lee M. HangerCharlevoix County Community

Foundation - Hanna Family Fund

Mr. and Mrs. Robert HanscomEstate of Victor E. HansenFleur and Leonard HarlanThe Harris Family Charitable FundBethany HarrisEleanor and Steven HarrisMr. and Mrs. William B. HarrisonDr. and Mrs. William A. HaseltineMelinda HassenThomas HassenTyler HassenMr. and Mrs. Michael HausKathryn L. Haw

THROUGH THE KITCHEN PARTY AT THE FOUR SEASONS RESTAURANT; ANSWER TO CANCER CYCLISTS; LABANSWER AND ITS EMPLOYEES


Mr. and Mrs. Robin HayesMs. Gale Hayman and

Dr. Richard S. BockmanHead Family TrustDonald B. Hebb Jr.Margaret J. HeiserAlexandra B. HelmsTad R. HerzBeth HickeyEd HicksHiggins Charitable TrustJames HigginsReid T. HironagaDr. and Mrs. Frank HoefflinPaul C. HoehneBurt M. Hoffman Attorney At Law, LLCChristopher HoganHogan Lovells US LLPJessica Holfman LujanKathleen and David HollowsHorrorHound

Mr. and Mrs. Richard C. Hosley IIEric HowardJohn HowardHudson Americas L.P.Kathleen HughesMaritza HurtadoHzW Environmental ConsultantsIdeal Image of DelawareCapt. Scott IngrahamIntegrus, LLCMr. and Mrs. Marc J. IsaacsMr. and Mrs. Seymour IsraelE. Marion JacknowDeborah and Arthur JacobsonThe James Jacobson Family FundKate and Jeff JaenickeGeorge and Janet Jaffin FoundationJakal Booster ClubJanklow FoundationElizabeth M. JenningsTina JichaDonald JohJohri Family Charitable FoundationAnne and Johnny JonesAustin JonesJP Morgan Chase FoundationRebecca and Michael JuneauDr. Basim KadhimMr. and Mrs. Neil R. KardosMr. and Mrs. Howard KayeMr. and Mrs. Jerrel W. KeeMr. and Mrs. Terry KellerMr. and Mrs. William KellerEdna KelleyVeronica and Ray KellyMr. and Mrs. Richard KernsKeurig Green MountainMr. and Mrs. Bradley D. KevernAlena KimKen KinslowWilliam KisslingMr. and Mrs. Brandon KistlerMark E. KleinJerry KleinmanRobert KlettShannon KlineKoko Fitclub of MinnesotaMiss Laine KomanMr. and Mrs. Richard F. KossikTakashi KousakaAndrew KratzJohn KrenickiIvan KriakovBrenda Kulick

Mr. and Mrs. Kevin KuntzPerry A. KupietzMr. and Mrs. David P. KuselMark KwanSheila LabrecqueMr. and Mrs. Benjamin LambertHarlos R. LarroweLaser ImageCarey F. LathropThe Jeremy Lau FundDr. Lena and Professor Peretz LavieMartha and Drahomir LazarThe League of Legends CommunityLaura LedfordElizabeth LeeMichelle LeedsMr. and Mrs. Ben LefkowitzMorris and Lillie Leibowitz

Charitable TrustMr. and Mrs. Craig LemleDavid LenderDr. and Mrs. Philip R. LesorgenMr. and Mrs. Francis L’EsperanceDr. Andrei LevinRichard and Emily Levin FoundationJohn S. LevyMary Lynne LevyWilliam LiLife Time Marketing, LLCAnthony LinTullia Lindsten, M.D., Ph.D., and

Craig B. Thompson, M.D.Mr. and Mrs. Jerry LisDaniel C. LitchfieldChris LloydBrad LoncarHeather LongLongboard Asset Management LLCTimothy and Leslie Lucas

Charitable FundWilliam C. LuciaBrian LuingDonald L. LundholmPeter LyonLynn E. LyonsMr. and Mrs. Bruce R. MacDonaldMacheist LLCDr. Thomas MackRobert S. MaddenMadhatter’s Tea PartyThomas MaherasChris & Melody Malachowsky

Family FoundationLaurie and Jay Mandelbaum

William MansfieldMr. and Mrs. Michael MarantoMariel FoundationBeverly and John MarinoJane Martin and Stuart KatzMr. and Mrs. Redge A. MartinMr. and Mrs. Steve MartinRichard A. MartiniMartins Construction CorporationMichael M. MarzbanJeffrey A. MasonMr. and Mrs. Allen R. MassDr. Philip MastmanEllen C. MathiasJohn D. MauroJeffrey S. MayRoy ‘Rem’ MayesDorothy McCabe and Lee KuntzDavid McElligottChristopher McGarrigalKate A. McKayChristine McKenneyRobert M. McKeonKelly McKernanVincent McLaughlinMr. and Mrs. Michael A. McMurphyDerek McTyierMedtronicMehul FundRichard Meier FoundationSusan F. MelsonThe Sue and Eugene Mercy, Jr.

Foundation, Inc.Joan MeyersMichael Edwards Direct, Inc.Mr. and Mrs. Galem W. MillardMr. and Mrs. Craig MillerDiane L. and Donald L. MillerBarry MinkoffJahid MirzaMr. and Mrs. John MitchellHiromasa MizushimaMJD Concepts, Inc.Esmail MobarakAfshin MomtazGordon and Betty Moore

FoundationMr. and Mrs. Paul D. MoranPauline K. MorganEmily MorningstarDr. Robert MoskowitzErik MouthaanDr. Jason MuchMr. and Mrs. Bill Mullins

Pamela Anne MurphyVanitha MurugesanMaria Isabel Nadal De PuigdorfilaJenks Necker Charitable FundDeborah Newsome-SmithKevin K. NickelBarbara NielsenJon NiteNorwalk High SchoolNotre Dame AcademyJohn NowakJeffrey NuechterleinBrandon NutterRebecca and Douglas ObletzMelissa and Charles O’BrienMr. and Mrs. Gregory A. OdleChristine OgataCarolyn J. O’HaraMr. and Mrs. James A. OlsonMr. and Mrs. John OrlandoDaniel O’ShaughnessyTwila I. O’SullivanElma and Fred OttoJoe OzielPacker Family Charitable FundMichael PalmerYvonne S. PalmerDr. Vernon L. PankoninLee A. PareeDarryl L. ParrishKelly and Gerry PasciuccoLasantha PathiranaJoseph A. Patrick Foundation, Inc.Camilo PatrignaniPatterson Companies Inc.China PavilionAlan PetersenJeffrey A. PetersonDr. and Mrs. Frank PetitioPew Charitable TrustsJohn C. PeyrebruneAshley R. PiggushMr. and Mrs. Patrick PijanowskiJames PintoMr. and Mrs. Michael J. PizzoGerald PolicastroWilliam PollockAna Luisa PontiMr. and Mrs. Robert A. PosnerAndrew W. PotashPPD Development, LPAustin J. PreslarPaul PresslerMr. and Mrs. Michael J. Price

T. Rowe Price Foundation, Inc.Puglisi Family 2014 Charitable

Giving FundQualcommRoberto QuartaIgor RabinRaces for AwarenessRenate and Walter RadosJames A. RandelTammy and Eric RasmussenTerrie L. RayReactive SystemsRecover Painting, LLCRed Hat, Inc.Douglas RedikerRichard B. ReedHulda and Michael RefermatDawn E. RefsellMatthew ReischlMr. and Mrs. Jerrid RezinChad E. RichmanKurt RiemenschneiderMr. and Mrs. Jonas J. RieterDr. Erika RileyMr. and Mrs. David RiparbelliMr. and Mrs. Herald L. RitchRobert P. RittereiserAnna RocklerRebecca RogersDr. and Mrs. Leon RootSteven M. Rosenberg FundMrs. Abraham RosenthalJane Rosenthal and Craig HatkoffBarry D. RoyFrancois R. RoyRichard P. RoyerLaurette RupRobert Rushton

It was an honor to play a small role in the process that will sustain cancer immunotherapy into the future.

Julian Suchman Team CRI runner, TCS New York City Marathon

MAKEUP ARTIST JESSICA HAZE


The Rust Family FoundationSallay Family FundStanley SaltzmanFrancine M. SandovalMr. and Mrs. Adarsh SarmaRose Ann ScamardellaScanning America, Inc.Heather SchimmelSchluter Systems L.P.William O. SchmaleLauren A. SchmidtRick SchnallKaren A. and Henry P. SchneiderMike SchoebenJune and Paul C. Schorr IIIDr. David N. SchrierSchulman Family FoundationHenry C. Schulte and Virginia M.

Schulte FoundationLarry R. SchunemanJames M. ScrivanichBrian SearcyHooman SedighiMr. and Mrs. Thomas L. SeifertKaren ShapiroStephen ShapiroJane SharpDan ShedrickCynthia SheetsShell Oil Company FoundationRocky John ShererRaechelle B. ShermanJonathan ShipmanThe Susan S. Shiva FoundationShowin’ for a CureMr. and Mrs. Brian D. SilvermanAnne SilversteinEdward R. SimmonsSimplistics, Inc.The Simpson FoundationLinda G. SingerNate SleeperLaura J. SloateLois V. SmigelMr. and Mrs. Gordon H. SmithMr. and Mrs. Jeffrey Q. SmithMary F. Smith Family FoundationNora M. SmithPatrick SmithMr. and Mrs. Scott SokolMr. and Mrs. Howard SolomonSolutions By Design II, LLCAnne SpencerWilliam Spero

Michael SpitzenbergerKristen Sproat ColleySt. Luke’s Lutheran ChurchPaul StaggEdgar StanleyBonnie M. and Robert J. StapletonThe Honorable and

Mrs. Kenneth W. StarrMichael StarrMary K. Steffens FoundationBeatrice SternPatricia StohlerBonnie and Tom StraussStuntz Family FoundationMayo S. StuntzSweet/Polak Charitable FundMarc TabahMr. and Mrs. Kok Chor TanJesyca TangJoshua L. TargoffNicki Taylor and the CuddlebugsJean and Kenneth TelljohannTennis League Network, LLCTexarkana Jeep Junkies ClubMr. and Mrs. Jeffery ThomasMarc ThomsonThomson ReutersMr. and Mrs. Andrew H. TischDr. and Rev. David C. TontonozWilliam TophamMr. and Mrs. Alex ToppinAlain TranchemontagneMr. and Mrs. John TrousdalePaul TrunkTTX CompanyMary Ann TuftTimothy F. TurittoAllen M. TurnerDr. Lynn H. TurnerUSPA Liz Freel ClassicNancy and Jim UtaskiUtility Contracting Co.Mr. and Mrs. Jeffrey K. Valentine Sr.Anne and Philip Vander HaarCsaba VandorJ.J. VenturiniVillage of Long Creek Maintenance CorporationThe Villages Theater CompanyMillie Viqueira and Steven MillerVMware FoundationJohn VogelMr. and Mrs. Lance Volland

The Kathleen B. and Charles R. Walgreen III Foundation

Robert B. WalkerRichard N. WalshBarbara WaltersCarrie L. WalworthJeff WareJoseph WarrenCarolyn and David WassermanWatermark LearningSandra J. WattierWeb Decisions GroupSteven E. WeigandThe Weingarten Schnitzer

FoundationHelen and Tom WellingWendell Family FoundationS. Kyle WessonElizabeth G. WeymouthGerald I. WhiteThe Wild UnknownDavid T. WileyJoanna WilliamsGreg WilsonPatricia M. WilsonMr. and Mrs. Dennis WinansGreg WirthMichael J. WisdomThe Wise Family TrustCarole and Michael WitteMichael WoinskyElaine and Jim WolfensohnGregg S. WolpertMr. and Mrs. William WorthingtonWowToyzMelissa Yannis-GrandStephen YegelwelStrauss ZelnickZenith Ventures, Inc.J.L. ZrebiecMr. and Mrs. Jeffrey ZuckerJoan R. ZuckermanMarc ZuckermanBarry Zurbuchen

Helen Coley Nauts SocietyThe Helen Coley Nauts recognizes donors who have included the Cancer Research Institute in their estate plans. Through deffered gifts, bequests, trusts, and other planned giving instruments, these thoughtful individuals safeguard the Institute’s financial future. The Society is named in honor of Helen Coley Nauts, CRI’s founder. If you would like to learn more about making a planned gift, please contact Rupinder Kaur at [email protected] or (212) 688-7515.

Estelle AbasPeter AdamsAbigail AldermanOlga AleskasMildred E. AlexanderFrederick E. AllardEdith M. AmateauPeggy AndersonAnonymous (6)Frances AntopolFreda S. ArmstrongGrace ArnoldGeneva A. ArthurMillie L. ArvanitesRuth AscherVirginia and Rex AshdownLee AsherBelle AshermanAlice AuerbachNorman W. AustinJeanne AvegnoElse BaierMaureen and Charles BakerOlga Baker

ANNUAL AWARDS DINNER AT THE METROPOLITAN CLUB; #WHITEOUTCANCER EVENT AT MEDIMMUNE/ASTRAZENECA; AND ANSWER TO CANCER CYCLING TEAM BRISTOL-MYERS SQUIBB


Marion BalenElla R. BanksMary R. BaqueDorothy BarbeauJeanne E. and Jacob A. BarkeyMr. and Mrs. Kenneth BarmoreConnie BarnesWilliam BarrFlorence and Ben BarrackRose BarrowIsabella Williams Bartholow and

Bruce Burdette BartholowEtta BaumEvelyn BeekmanFrank L. BellGermaine BeneschWilliam A. BerkeyStuart S. BernardLucille BernotHerta J. BernsteinVincent L. BesseyLinda BielatGrace M. BishopJohn BittelGuy BjorkmanLeslie J. BlainAnna H. BlanksteinPaula J. BlatterRuth Evelyn BodbylEleanor BodnarRonald J. BogusNancy E. and Lawrence H. BonanderMary BorbeckRita BorensteinRobina C. BouchardTed J. Boulanger TrustAnna Isabel BoydHugh R. BoydBarbara Brown BoyerFrederick BrandJoy B. BreidlingLucille BrentsA. Arthur BressmanBrian M. BrewerVictor E. BrollAlbert N. BrooksMinnie E. BrownVirginia BrunerAlfred R. BrunnerAnne Luise BuergerLucille A. BulandMary C. BundyArthur BurkhardtLois M. Burns and Robert W. Burns

Dale T. ButterwickJoy Biggs ButtleRaymond V. ByrneAnn W. CalaskiMarilyn and David CallahanTracy CampbellAngelina CarboneAlfred CarlucciJulia CarlucciPandora Rudland CarrollDonald O. CarswellMelba CaseMary Elizabeth CattoDoris M. ClaninWilliam James ClappRodney CobbWilliam H. CoffeeBernice CohnGwendolyn ColburnMr. and Mrs. Raymond ColeEdythe E. ColemanBradley L. Coley Jr.Louis ComedyPrudence CometaPhyllis L. ConleyVivian E. Conner and Ross I. ConnerLottie M. and Charles H. CookSalvatore CorsaroAudrey CowanRose Marie CraigEleanor H. CromleyElmira CrosbyJulia B. and John R. CurtisVincent D’AmicoAnnabelle L. DanzigCarleen V. DavisAlice DawesAileen Adele De LongEustis DearbornRichard M. DeMartiniEmma DetersCarolyn S. DetweilerBetty DisbrowAdelaide J. DodgeSandford DodyMichael DornerMary Ann DrausBlanche Elizabeth EckertsRita EggertDorothy M. EiserEarl R. ElliottPauline E. ElliottRalph EnderbyRuth Engelberg

Valera L. EnnisHelen EpsteinNathan EpsteinMax G. EriksenHelen B. EsokaitFlorence L. and Ned A. EtkinJuanita M. EvansMary S. FadeleyHelen Jean FalkHerbert Lynn FannBarbara FeldmanRobert I. FendrichCarlos A. FerrerAdelaide E. FerrisLouise Egdorf FescineElsie K. FilonchikMary H. and Frances E. FloodJosephine FontiFlorence A. ForniBernard W. ForrestCarole D. FranklinClay FrazierLucille O. FrenchAlice M. FriedAnne FruhnerLena Silverstein FuhrmanJames GaglianoGay H. GahaganZoltan GaldiEugene G. GallantPeter GallantMollie E. GangSophie GarafolaSalvador GarciaCarole GardnerB.I. GarlinghouseFritz GautschiThomas J. GearingE. Yvonne and William O. GeisertStella GentileMildred GentryPenelope M. GeorgiadisMercedes C. GerhardPatricia J. GetsfriedJanet M. GiffordRegina GilmourSteven D. GinsbergEdna E. GlaesselEleanor GoldbergPhilip GoldblattRaymond J. GordinierDoris GordonJean R. and John G. GosnellNorman Gottlieb

Dorothy M. GrahamE. Ruth GrantAnnette and Owen GrayBernice E. GrilleauxFloyd Dale GrishamZoe S. GroveNoreen Bryce GrueblRonald J. GuglielminoAnna GuhringMarianne C. HafnerJeanine HairNelle B. HaireAdrian Leroy HallDiane HamMr. and Mrs. Virgil HambyFrances E. HannemanThe Hansen TrustLydia C. HansonLoretta D. HardyMark L. HaritonEvelyn H. HarrisLori HarrisOttis C. HarrisHelaine T. HarrisonYetta HatchAnne M. HauserJames Leon HawkinsMargaret HaymanClarence E. HedbergDonald P. HeimVirginia HemmeRobert J. HendryFredrick Charles HenneSenora HenryMarion HewettKay HiltonMargot HoffmannNurine HokeEva M. HolmesDiane and Don HolmesNellie HuffGrace M. HumphreyMary L. HutchinsIdell E. and Fred W. IltnerMadeline InguagiatoRuby R. JankiewiczLynn and Eldon JasperWarren R. JecklinDoreen and Basil JoffeRuth Harvey JohnsonDoris KabatRosemary KaplanSally J. KaplanDavid Katz

Sara KatzBertha E. KaufmanSamuel KayBlanche C. KellyJean KempHugh W. KennedyMercedes E. KentElsie E. KielCorinne KiellTheresa A. KielyMary B. Kilroe and Edward L. Kilroe Barbara KincaideHilda KirsonShirlene KisakMarilyn and Robert KlettRuth and Hugo Klotz

Anne KochInez G. KochTruby Joy KohlMr. and Mrs. Harry KompanekJuanita and Fred KoorsHarry A. KrausMary T. KrausNaomi P. KruseMurray KupfermanHiroko KyubaRose LachowSidney G. LaDueAnna LagsteinC. Linda LambertJewell Marie LampkinMarguerite Landis

ANSWER TO CANCER CYCLING TEAM W2O; #WHITEOUTCANCER SUPPORTERS AT NBC TODAY SHOW PLAZA

Louise G. LaneCaryl Lou LangfordElizabeth S. LarkinAnneMarie LaValleMildred LeifferFlorence and Edgar LesliePolly Annenberg LeveeJames F. LevensFrances LeventrittBetty Lou LevinEsther LevineBeatrice LevySimon LifshatzFrancis R. LindenHarvey A. LindenPatricia A. LindnerGeorge H. LindskogRoseline LissakFrances M. LizakJohanna LoebRuby Q. LokensgardPeter J. LommenBonnie LongAlbie A. Adams LovingMadeline LukowitzMr. and Mrs. William H. LyfordGertrude A. LynchHjordes Diane LyttleEleanor D. MacCrackenEmilie MachalinskiCatriona MacleodWilliam S. MaddenboroughDavid MadsenHenrietta MalbinHerbert J. MaletzIsabelle C. MaloneAnna MalowanyJohn Malowany TrustFerne MagialardoMeyer MarcusB.M. MarinkoGenevieve MartinLouemma MartinLowell A. MartinRaleigh L. MartinBlanca Mattalia-WyrzykowskiMildred G. MatzDonald MaurerLourdes MayuyuMargaret MazzeyMichael I. McBrideHelen McCannCecil McClernonAnnette McDonald

Sharon H. McGowanJ. Donald McKinney Jr.Norma J. McPhersonJan MearsGrace Muriel MecchiJoan MeltesenNancy Jeanne MerkelSidney MeskinEthel L. MeyerEzilda MichelHelen T. MiddletonDorothy Mae MillerWilliam D. MillerAlex MitchellMaha MohamedMr. and Mrs. Charles G. MooreJanet P. MorganMaza D. MorrisLouise and Peter MoseychukBryant A. MuenzenAlexander MunchweilerIrene R. and Martin F. MurphyJudith K. MurphyKathryn T. MurphyThomas P. MurrayNaomi MyersMayumi Nakagawa and John K. LaiRita NasserAlice A. NautsPatricia NavarroPaula M. NealBarbara Lynne NelsonRose E. NelsonJean Marie NewcomerFreda E. Newton

and William E. Newton Herb H. NicholsBernard R. NiewoehnerGeneva W. NolenJacques C. NordemanMary M. NowakMary NunezDorothy B. NurickMargaret M. and Harry A. OakNora OdetsArvilla OgdenMichele A. OgnibeneRoselyn R. OlkenAlice OrlichMary O’RourkeAnna and Paul OschwaldAlbert OttingerLily Pace and Floyd Pace Marjorie W. Packwood

Erma N. PanfilioAndrew Reid PatonEleanor T. PattersonCarmen F. PattiFoster Clae PattonFrederick V. PayneNancy Elizabeth PeaseApril PeckDonald H. PeperAgnes PhelpsElizabeth F. PhillipsJohn PiercyHarriet-Anne PiersonRochelle PinzCynthia Joy PlattDorothy PlumbMabel PlunkettNick J. PokeaDavid M. PolenEsther PosinRichard PotruchDespina PoulosClifford PreskyJoyce A. PrimeDorothy S. PritchardAspasia RadoumisCarol Diane RankenJames B. RansohoffEsther ReedHarry Delos ReichHelen RelkinFloris J. RenkLaDonna ReynoldsJames F. RiceFlorence V. RichardsonAdam J. RichterVirginia L. RiddleRobert T. RidleyMichael RileyAdeline RingeisenDr. Fred RingelVeronica A. RoseSusan RosenbergIlene RothLeah RothMoises RubianoDorothy and Ernest RueppelGloria RuminskyHedwig SalzerMargaret E. SammonsLydia B. ScannellGertrude SchellingMartha SchnellerLouise S. Schoenke

Virginia SchuettpelzHelen R. SchuttRuth SchwartzmanRev. Harold Bend SedgwickDorothy K. SefcovicFrancine SegallClara SenkNatalie ShebsDorothy M. SheeseMargaret SheetsDonald SherwoodRenee and Irwin ShishkoLaura M. SidenerLottie SiegelKatherine U. SilvaBelle V. SilversteinAugusta SimonRoma SinclairEstelle SingerJean V. SirlesAlice Jean SmithCatherine M. SmithClarence SmithMr. and Mrs. Ernest B. SmithHoward G. SmithKevin L. SmithPatricia SmithWillie Mae SmithRuth SneveVera Marie SniderEsther and Harold SohmerFred E. SpencerJacqueline SpencerWilliam SprengerRemy R. SprouseBrenda M. St. JamesGerald J. SteinbergLeopold SteindeckerAnna StephanRobert L. StevensMary Malcolm StilesJohn StrangFay Strout and Laurence Cecil Strout Frieda Coons StudleyDorothy H. SullivanMyrtle B. SummersAgnes Katscher SunleyJohn SuponMary and James SuthardMary Carol TalericoMaureen TannehillMelvin G. TaylorGeorge C. Thomas Jr.Carl E. Thomas

Geraldine E. ThomasOverton Arnold ThompsonViola Mae ThompsonAnita and John R. TimmelCarola S. TrierJessie C. TrippJohn D. TurkelZelda M. UthePaul E. Van CleveWilliam R. VassJosephine S. VillemanMyrtle H. and Antone L. VinelliAnne D. VintonPaul H. VolpeLinda VonoEsther and Stanley WadeEthel WagnerDavid WalkerRobert B. WalkerThomas WalshJulia WalzLea WardIrene M. WatkinsDorothy WaughIone A. and Albert L. WeickertRose C. WeiselElizabeth A. WeiserLeonard WeissRobert P. WestAnna M. WheelerLois V. WheelerAgnella L. WidmerGeneva K. WidmerMargaret WiegandtSaul J. WienerLoretta M. WigginsLorna Katherine WilkinsonFrancis I. and Harriet B. WilksJosephine H. WilliamsOra Brown WindleMr. and Mrs. Norman J. WoodhamsFrederick W. WoodworthCarolyn and Bill WoodyJohn A. WoottonJosephine WoottonNettie WrightEthel R. YoungMarion E. YoungbergGloria ZainoMarion ZellRaelynn and Steve Ziegler

Centennial CircleThe Centennial Circle celebrates donors who have made a lifelong commitment to supporting the Cancer Research Institute. Members of this loyal group have made 75 or more gifts to CRI during their lifetime.

Anonymous (2)Ellen BeloffMr. and Mrs. Ira M. BoskeyBrian M. BrewerLauren B. BurnsHarriet E. CharlesMr. and Mrs. Irving CohenAileen ColeSelma DavidsonArchibald M. Denny IIIMr. and Mrs. Stephen C. ElkinRhoda FischmanAnne E. GentileMr. and Mrs. Gary R. GinsbergMr. and Mrs. Leonard GoldOliver R. Grace Jr.Helen A. GreenRenee A. HarrisHarvey A. HerbertMrs. Stephen M. KellenCol. Richard C. KowalskiMr. and Mrs. Elliot LeitnerMr. and Mrs. Michael LevyCharles J. LurieMr. and Mrs. Charles Lyttle IIThomas G. MendellMr. and Mrs. Arthur NassoJacques C. NordemanBernadette NuzzoMaxwell D. OsborneEsther RavinMr. and Mrs. Jonas J. RieterMr. and Mrs. Milton S. RubinClifford M. RutterJoyce SchumerMr. and Mrs. Sydney ShumanMr. and Mrs. Brian D. SilvermanMr. and Mrs. Marvin StillmanWilliam TracyTimothy D. TuckerMr. and Mrs. Everett L. WessnerAlan N. WhiteFlorence Wisler


Donor trust is something we value above all else. To earn and maintain this trust, we hold ourselves to the highest standards of accountability and transparency when communicating the

financial health of this organization. Seeking to extract maximum impact from every dollar donated, we fund strategically and invest responsibly, keeping an eye to the long view of progress while remaining nimble enough to respond to new opportunities. Our financial records are kept according to best accounting practices, and we open our books annually for inspection and verification by independent auditors.

EisnerAmper has conducted an independent audit of the Cancer Research Institute’s financial activities for fiscal year 2016 (July 1, 2015, to June 30, 2016). We provide highlights here, and you can access our complete audited financial statements on our website atcancerresearch.org/financials.F

INA

NC

IAL

HIG

HL

IGH

TS

87 PERCENT OF EXPENSES DEDICATED TO PROGRAMS

$336 MILLION INVESTEDSINCE 1953

Your Gift at Work

The continued financial strength of this organization stems not only from the generosity of our donors, but also from the rigorously high standards of accountability to which we hold ourselves.

Alfred R. Massidas Chief Financial Officer

PUBLIC SUPPORT & REVENUE (Unrestricted)

$33.7MM

Special Events$2.7MM, 8%

Bequests & Memorials$2.0MM, 6%

Contributions$26.9MM, 80%includes $9.9MM raised in prior years for FY2016 operations

Investments & Other$2.2MM, 6%

OPERATING EXPENSES

$31.5MM

Administration $1.2MM, 4%

Marketing & Fundraising$2.8MM, 9%

Education$4.8MM, 15%

$23.6MM awarded minus $909K in early terminations from grants made in prior years

Research$22.6MM, 72%


Volunteer scientific and business leaders help the Cancer Research Institute, not only through academic and financial support, but also through astute governance and active

participation in the organization’s initiatives.

BOARD OF TRUSTEES

CHAIRMEN

Paul C. ShiverickCo-FounderSeminole Management Company, Inc.New York, NY

Andrew K. TsaiManaging PrincipalChalkstream Capital Group, L.P.New York, NY

VICE CHAIRMEN

Edgar R. BernerPartnerJohn Lang, Inc.New York, NY

John B. FitzgibbonsChairman and CEOBasin Holdings US LLCNew York, NY

Donald J. GogelChairman and CEOClayton, Dubilier & Rice, LLCNew York, NY

Jacques C. NordemanChairmanNordeman Grimm, Inc.New York, NY

Andrew M. PaulManaging General PartnerEnhanced Equity FundsNew York, NY

TREASURER

Geoffrey O. ColeyInternational Business HeadMitsubishi UFJ Securities (USA), Inc.New York, NY

SECRETARY

Thomas G. MendellPrivate InvestorT.G. Mendell Corp.New York, NY

BOARD

Yacov ArnopolinPortfolio Manager, Emerging MarketsPIMCONew York, NY

Peter L. BloomBrooklyn, NY

Jennifer L. BrorsenBronxville, NY

James M. CitrinLeader, CEO PracticeSpencer StuartStamford, CT

Maurice J. CunniffeChairman and CEOVista Capital CorporationGreenwich, CT

W. Robert DahlPrincipalWRD CapitalDarien, CT

GO

VE

RN

AN

CE

&

GU

IDA

NC

E Providing Expert Oversight

Glenn J. DeSimoneGreenwich, CT

John E. EckersonRye, NY

Sean P. FaheyFounding Member andCo-Chief Investment OfficerClaren Road Asset ManagementNew York, NY

Margot E. FreedmanLarchmont, NY

Oliver R. Grace Jr.PresidentAssociated Asset Management, Inc.Palm Beach, FL

Sandra Coudert GrahamOyster Bay, NY

Michael M. KellenDirector of First Eagle Holdings, Inc.Vice Chairman of First Eagle Investment Management, LLCNew York, NY

Alexander P. LynchPartnerWhite Deer EnergyNew York, NY

Brian RianoCo-Founder and CEOClaren Road Asset ManagementNew York, NY

Lief D. RosenblattPartner ENE Investco ManagementNew York, NY

Frank V. SicaPresidentTailwind CapitalNew York, NY

James A. SternChairman and FounderThe Cypress Group, LLCNew York, NY

Michael B. TargoffVice Chairman of the Board of DirectorsLoral Space & CommunicationsNew York, NY

Diane TuftNew York, NY

Heidi J. UeberrothDirectorPebble Beach CompanyPebble Beach, CA

Lauren S. VeronisNew York, NY

Ronald G. WeinerPresidentPerelson Weiner LLPNew York, NY


CRI trustees are fully engaged in our mission because each of us believes in the potential of immunotherapy to conquer all cancers, and each has seen how CRI is able to transform this potential into reality for many cancer patients today.

John B. Fitzgibbons Chairman and CEO, Basin Holdings US LLCVice Chairman, CRI Board of Trustees

Jim WeissFounder and CEOW2O GroupSan Francisco, CA

Peter ZhouSenior Managing DirectorCoatue ManagementNew York, NY

TRUSTEES EMERITI

Carter F. BalesChairman and Managing DirectorNewWorld Capital Group, LLCNew York, NY

Howard P. BerkowitzHPB AssociatesNew York, NY

Donald G. CalderChairmanClear Harbor Asset ManagementNew York, NY

Stuart P. DavidsonManaging DirectorLabrador VenturesSan Francisco, CA

Bruce D. DixonRetired PartnerErnst & YoungGreenwich, CT

Mrs. Charles G. GambrellCharlotte, NC

William O. GrabeAdvisory DirectorGeneral Atlantic LLCGreenwich, CT

Joyce GreenWesthampton Beach, NY

Ann W. JacksonNew York, NY

Arthur L. JacobsonVice President, InvestmentsSmith BarneyIndian Wells, CA

Robert A. PosnerManaging DirectorCommonwealth Holding, LPBrookline, MA

Julian H. Robertson Jr.ChairmanTiger Management, LLCNew York, NY

Winthrop H. Smith Jr.ChairmanSummit Ventures NE, LLCWarren, VT

ASSOCIATE BOARD

CHAIRMAN

Tyler HassenPresidentBasin PowerNew York, NY

MEMBERS

Adler BernardCounselJPMorgan Chase & Co.New York, NY

Jennifer Box, CFAManaging DirectorOaktree Capital Management, L.P. New York, NY

Rada CevherBusiness DevelopmentWealth-XNew York, NY

Eash CumarasamyChief Financial OfficerBasin Industries New York, NY

Edward DonkorPrincipal, Energy Investment TeamPine Brook PartnersNew York, NY

Michael FisherVice PresidentEnhanced Equity FundsNew York, NY

Andrew GoldmanManaging DirectorAnchorage Capital GroupNew York, NY

Niko Gubernator, Ph.D.Chief Executive OfficereMoleculesLa Jolla, CA

Nick HammerschlagFounder and Managing PartnerMartellus HoldingsNew York, NY

Samantha KnapikConsultantFortress Investment GroupNew York, NY

Trent KososkiPrincipalEnergy Capital PartnersShort Hills, NJ

Maggie MooreVice President, Urban Investment Group Goldman SachsNew York, NY

Ashton ValenteGeneral CounselBasin HoldingsNew York, NY

SCIENTIFIC ADVISORY COUNCIL

DIRECTOR

James P. Allison, Ph.D. The University of Texas MD Anderson Cancer CenterHouston, TX

ASSOCIATE DIRECTORS

Glenn Dranoff, M.D. Novartis Institutes for BioMedical ResearchCambridge, MA

Carl F. Nathan, M.D. Weill Cornell MedicineNew York, NY

Ellen Puré, Ph.D. University of Pennsylvania Philadelphia, PA

Robert D. Schreiber, Ph.D. Washington University School of MedicineSt. Louis, MO

Jedd D. Wolchok, M.D., Ph.D. Memorial Sloan Kettering Cancer Center and Ludwig Cancer ResearchNew York, NY

MEMBERS

Frederick W. Alt, Ph.D. Boston Children’s Hospital and Harvard Medical SchoolBoston, MA

Richard Axel, M.D. Columbia University Medical CenterNew York, NY

Nina Bhardwaj, M.D., Ph.D. Tisch Cancer Institute, Icahn School of Medicine at Mount SinaiNew York, NY

Harvey Cantor, M.D.Dana-Farber Cancer InstituteBoston, MA

Jonathan S. Cebon, Ph.D., FRACPAustin Health/Ludwig Cancer ResearchMelbourne, Australia

Vincenzo Cerundolo, M.D., Ph.D. MRC Human Immunology Unit, University of OxfordOxford, United Kingdom

Max D. Cooper, M.D. Emory University School of MedicineAtlanta, GA

Lisa M. Coussens, Ph.D.Knight Cancer Institute Oregon Health & Science UniversityPortland, OR

Peter Cresswell, Ph.D. Yale University School of MedicineNew Haven, CT

Charles G. Drake, M.D., Ph.D. NewYork-Presbyterian/ Columbia University Medical Center New York, NY

Michael L. Dustin, Ph.D. University of Oxford Oxford, United Kingdom

Richard A. Flavell, Ph.D., FRS Yale University School of MedicineNew Haven, CT

Thomas F. Gajewski, M.D., Ph.D. The University of ChicagoChicago, IL

Laurie H. Glimcher, M.D. Dana-Farber Cancer InstituteBoston, MA


Philip D. Greenberg, M.D. University of Washington School of Medicine and Fred Hutchinson Cancer Research CenterSeattle, WA

Axel Hoos, M.D., Ph.D.GlaxoSmithKlineCollegeville, PA

Patrick Hwu, M.D.The University of Texas MD Anderson Cancer CenterHouston, TX

Elizabeth M. Jaffee, M.D.The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of MedicineBaltimore, MD

Carl H. June, M.D. Abramson Cancer Center, Perelman School of Medicine at the University of PennsylvaniaPhiladelphia, PA

Michael Kalos, Ph.D.Eli Lilly & CompanyNew York, NY

Michael Karin, Ph.D. University of California, San DiegoLa Jolla, CA

John M. Kirkwood, M.D.University of Pittsburgh Cancer InstitutePittsburgh, PA

George Klein, M.D., D.Sc. Karolinska InstituteStockholm, Sweden

Alexander Knuth, M.D. National Center for Cancer Care and Research, Hamad Medical CorporationDoha, Qatar

Lewis L. Lanier, Ph.D. University of California, San FranciscoSan Francisco, CA

Hyam I. Levitsky, M.D.Juno TherapeuticsSeattle, WA

Dan R. Littman, M.D., Ph.D. NYU Langone Medical CenterNew York, NY

Nils Lonberg, Ph.D.Bristol-Myers SquibbMilpitas, CA

Tak W. Mak, Ph.D., D.Sc., FRSCThe Campbell Family Institute for Breast Cancer Research at Princess Margaret Hospital, University Health Network, University of TorontoToronto, Canada

Philippa C. Marrack, Ph.D. National Jewish Health and the University of Colorado DenverDenver, CO

Cornelis J.M. Melief, M.D., Ph.D. Leiden University Medical CenterLeiden, The Netherlands

Ira Mellman, Ph.D. GenentechSouth San Francisco, CA

Malcolm A.S. Moore, D.Phil.Memorial Sloan Kettering Cancer CenterNew York, NY

Lee Nadler, M.D.Dana-Farber Cancer InstituteBoston, MA

Kunle Odunsi, M.D., Ph.D. Roswell Park Cancer InstituteBuffalo, NY

Drew M. Pardoll, M.D., Ph.D. The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of MedicineBaltimore, MD

Klaus Rajewsky, M.D. Max-Delbrück Center for Molecular MedicineBerlin, Germany

Anjana Rao, Ph.D. La Jolla Institute for Allergy and Immunology, Sanford Consortium for Regenerative MedicineLa Jolla, CA

Jeffrey V. Ravetch, M.D., Ph.D. The Rockefeller UniversityNew York, NY

Stanley R. Riddell, M.D. Fred Hutchinson Cancer Research CenterSeattle, WA

Alexander Y. Rudensky, Ph.D. Memorial Sloan Kettering Cancer CenterNew York, NY

Bijan Safai, M.D., D.Sc.New York Medical CollegeValhalla, NY

Shimon Sakaguchi, M.D., Ph.D. Immunology Frontier Research Center, Osaka UniversityOsaka, Japan

Lawrence E. Samelson, M.D. National Cancer Institute, NIHBethesda, MD

Hans Schreiber, M.D., D.MSc., Ph.D. The University of ChicagoChicago, IL

Ton N. Schumacher, Ph.D.The Netherlands Cancer Institute and Kite Pharma Amsterdam, The Netherlands

Craig L. Slingluff Jr., M.D. University of Virginia School of MedicineCharlottesville, VA

Mark J. Smyth, Ph.D.QIMR Berghofer Medical Research InstituteQueensland, Australia

Pramod K. Srivastava, M.D., Ph.D. University of Connecticut Health CenterFarmington, CT

Susumu Tonegawa, Ph.D. Massachusetts Institute of TechnologyCambridge, MA

Giorgio Trinchieri, M.D. National Cancer Institute, NIH Frederick, MD

Emil R. Unanue, M.D. Washington University School of MedicineSt. Louis, MO

Ulrich H. von Andrian, M.D., Ph.D. Harvard Medical School and Boston Children’s Hospital, Boston; The Ragon Institute of Massachusetts General Hospital, MIT, and Harvard UniversityCambridge, MA

Robert H. Vonderheide, M.D., D.Phil.Abramson Cancer Center, Perelman School of Medicine at the University of PennsylvaniaPhiladelphia, PA

Hao Wu, Ph.D. Boston Children’s Hospital and Harvard Medical SchoolBoston, MA

Cassian Yee, M.D. The University of TexasMD Anderson Cancer CenterHouston, TX

Rolf M. Zinkernagel, M.D., Ph.D.University of ZürichZürich, Switzerland

CVC TRIALS NETWORK

DIRECTOR AND SCIENTIFIC ADVISORY COMMITTEE CHAIR

Jedd D. Wolchok, M.D., Ph.D.Memorial Sloan Kettering Cancer Center and Ludwig Cancer ResearchNew York, NY

SCIENTIFIC ADVISORY COMMITTEE

Nina Bhardwaj, M.D., Ph.D.Icahn School of Medicine at Mount SinaiNew York, NY

Jonathan S. Cebon, Ph.D., FRACPAustin Health/Ludwig Cancer ResearchMelbourne, Australia

George Coukos, M.D., Ph.D.University Hospital of Lausanne (CHUV)Lausanne, Switzerland

Lawrence Fong, M.D.University of California, San FranciscoSan Francisco, CA

Dirk Jäger, M.D.National Center for Tumor Diseases, University of Heidelberg Heidelberg, Germany

Elizabeth M. Jaffee, M.D.Johns Hopkins University School of MedicineBaltimore, MD

Carl H. June, M.D.Abramson Cancer Center, Perelman School of Medicine at the University of PennsylvaniaPhiladelphia, PA

Matthew F. Krummel, Ph.D.University of California, San FranciscoSan Francisco, CA

Kunle Odunsi, M.D., Ph.D.The Roswell Park Cancer InstituteBuffalo, NY

Antoni Ribas, M.D., Ph.D.UCLA Medical CenterLos Angeles, CA

Michel Sadelain, M.D., Ph.D.Memorial Sloan KetteringCancer CenterNew York, NY

Neil H. Segal, M.D., Ph.D.Memorial Sloan Kettering Cancer CenterNew York, NY

Andrew G. Sikora, M.D.Baylor College of MedicineHouston, TX

Craig L. Slingluff Jr., M.D.University of Virginia Cancer CenterCharlottesville, VA

Pramod K. Srivastava, M.D., Ph.D.University of Connecticut HealthFarmington, CT

Marcel R.M. van den Brink, M.D., Ph.D.Memorial Sloan Kettering Cancer CenterNew York, NY

Robert H. Vonderheide, M.D., D.Phil.Abramson Cancer Center, Perelman School of Medicine at the University of PennsylvaniaPhiladelphia, PA

E. John Wherry, Ph.D.Abramson Cancer Center, Perelman School of Medicine at the University of PennsylvaniaPhiladelphia, PA


FINANCE, INTELLECTUAL PROPERTY, CLINICAL TRIALS MANAGEMENT, AND ADMINISTRATION

CANCER RESEARCH INSTITUTEAdam KolomVanessa M. Lucey, Ph.D., MBAJill O’Donnell-Tormey, Ph.D.

LUDWIG CANCER RESEARCHPär Olsson, Ph.D. Aileen Ryan Jonathan Skipper, Ph.D.Ralph Venhaus, M.D.

GLOBAL CLINICIAN AND SCIENTIST MEMBERSHIP

UNITED STATES• James P. Allison, Ph.D.,

The University of Texas MD Anderson Cancer Center

• Shahab Asgharzadeh, M.D., University of Southern California

• Djordje Atanackovic, M.D., University of Utah

• Mark Awad, M.D., Ph.D., Dana-Farber Cancer Institute

• Nina Bhardwaj, M.D., Ph.D., Icahn School of Medicine at Mount Sinai

• Margaret Callahan, M.D., Ph.D., Memorial Sloan Kettering Cancer Center

• Timothy A. Chan, M.D., Ph.D., Memorial Sloan Kettering Cancer Center

• Aude G. Chapuis, M.D., Fred Hutchinson Cancer Research Center

• Hearn Jay Cho, M.D., Ph.D., Icahn School of Medicine at Mount Sinai

• Adam D. Cohen, M.D., University of Pennsylvania

• Patrick Dillon, M.D., University of Virginia Health System

• Gavin P. Dunn, M.D., Ph.D., Washington University School of Medicine

• Lawrence Fong, M.D., University of California, San Francisco

• Leena Gandhi, M.D., Ph.D., NYU Langone Medical Center

• Sacha Gnjatic, Ph.D., Icahn School of Medicine at Mount Sinai

• Philip D. Greenberg, M.D., Fred Hutchinson Cancer Research Center, University of Washington

• F. Stephen Hodi Jr., M.D., Dana-Farber Cancer Institute, Harvard Medical School

• Siwen Hu-Lieskovan, M.D., Ph.D., UCLA Medical Center

• Elizabeth M. Jaffee, M.D., Johns Hopkins University School of Medicine

• Carl H. June, M.D., University of Pennsylvania

• Achim Jungbluth, M.D., Memorial Sloan Kettering Cancer Center

• Thomas J. Kaley, M.D., Memorial Sloan Kettering Cancer Center

• John M. Kirkwood, M.D., University of Pittsburgh Medical Center

• Matthew F. Krummel, Ph.D., University of California, San Francisco

• Alexander M. Lesokhin, M.D., Memorial Sloan Kettering Cancer Center

• Kunle Odunsi, M.D., Ph.D., Roswell Park Cancer Institute

• Hideho Okada, M.D., Ph.D., University of California, San Francisco

• Drew M. Pardoll, M.D., Ph.D., Johns Hopkins University School of Medicine

• Marshall R. Posner, M.D., Icahn School of Medicine at Mount Sinai

• Osama E. Rahma, M.D., University of Virginia Health System

• David A. Reardon, M.D., Dana-Farber Cancer Institute

• Antoni Ribas, M.D., Ph.D., UCLA Medical Center

• Michel Sadelain, M.D., Ph.D., Memorial Sloan Kettering Cancer Center

• Yvonne Saenger, M.D., Columbia University Medical Center

• Jonathan D. Schoenfeld, M.D., M.Phil., MPH, Dana-Farber Cancer Institute

• Neil H. Segal, M.D., Ph.D., Memorial Sloan Kettering Cancer Center

• Padmanee Sharma, M.D., Ph.D., The University of Texas MD Anderson Cancer Center

• Andrew G. Sikora, M.D., Ph.D., Baylor College of Medicine

• Craig L. Slingluff Jr., M.D., University of Virginia Health System

• Alexandra Snyder Charen, M.D., Memorial Sloan Kettering Cancer Center

• Pramod K. Srivastava, M.D., Ph.D., University of Connecticut School of Medicine

• Mario Sznol, M.D., Yale Cancer Center

• Suzanne L. Topalian, M.D., Johns Hopkins University School of Medicine

• Cornelia L. Trimble, M.D., Johns Hopkins University School of Medicine

• Takemasa Tsuji, Ph.D., Roswell Park Cancer Institute

• Marcel R.M. van den Brink, M.D., Ph.D., Memorial Sloan Kettering Cancer Center

• Robert H. Vonderheide, M.D., D.Phil., University of Pennsylvania

• Ralph R. Weichselbaum, M.D., University of Chicago

• E. John Wherry, Ph.D., University of Pennsylvania

• Jedd D. Wolchok, M.D., Ph.D., Memorial Sloan Kettering Cancer Center, Ludwig Cancer Research

• Cassian Yee, M.D., The University of Texas MD Anderson Cancer Center

• Dmitriy Zamarin, M.D., Ph.D., Memorial Sloan Kettering Cancer Center

• Hassane M. Zarour, M.D., University of Pittsburgh Medical Center

• Lei Zheng, M.D., Ph.D., Johns Hopkins University School of Medicine

EUROPE• Maha Ayyoub, Ph.D., Institut

Gustav Roussy, Villejuif, France• Luigi Buonaguro, M.D., National

Cancer Institute Pascale, Italy• Vincenzo Cerundolo, M.D., Ph.D.,

University of Oxford, United Kingdom

• George Coukos, M.D., Ph.D., University Hospital of Lausanne, Switzerland

• Jessica Cecile Hassel, M.D., University Clinic of Heidelberg, Germany

• Dirk Jäger, M.D., University Clinic of Heidelberg, Germany

• Elke Jäger, M.D., Krankenhaus Nordwest, Germany

• Lana E. Kandalaft, Pharm.D., Ph.D., University Hospital of Lausanne, Switzerland

• Judith Kroep, M.D., Ph.D., Leiden University Medical Center, The Netherlands

• Simon A. Laban, M.D., University of Ulm, Germany

• James Larkin, FRCP, Ph.D., The Royal Marsden NHS Foundation Trust, United Kingdom

• Xin Lu, Ph.D., University of Oxford, Ludwig Cancer Research, United Kingdom

• Cornelis J.M. Melief, M.D., Ph.D., Leiden University Medical Center, The Netherlands

• Mark R. Middleton, M.D., Ph.D., University of Oxford, United Kingdom

• Dario Neri, Ph.D., Swiss Federal Institute of Technology Zürich, Switzerland

• Christian Ottensmeier, M.D., Ph.D., FRCP, University of Southampton, United Kingdom

• Pedro J. Romero, M.D., University Hospital of Lausanne, Switzerland

• Daniel E. Speiser, M.D., University Hospital of Lausanne, Switzerland

• Danila Valmori, Ph.D., Centre de Lutte Contre Le Cancer Nantes-Atlantique, France

• Nicolas Van Baren, M.D., Ph.D., Université Catholique de Louvain, Ludwig Cancer Research, Belgium

• Maries van den Broek, Ph.D., University of Zürich, Switzerland

• Benoit J. Van den Eynde, M.D., Ph.D., Université Catholique de Louvain, Ludwig Cancer Research, Belgium

• Pierre van der Bruggen, Ph.D., Université Catholique de Louvain, Ludwig Cancer Research, Belgium

• Sjoerd Henricus van der Burg, Ph.D., Leiden University Medical Center, The Netherlands

• Magnus von Knebel Doeberitz, M.D., University Clinic of Heidelberg, Germany

• Alfred Zippelius, M.D., University of Basel, Switzerland

ASIA• Shinichi Kageyama, M.D., Mie

University School of Medicine, Japan

• Alexander Knuth, M.D., National Center for Cancer Care and Research, Hamad Medical Corporation, Qatar

• Eiichi Nakayama, M.D., Ph.D., Kawasaki University of Medical Welfare, Japan

• Hiroyoshi Nishikawa, M.D., Ph.D., National Cancer Center Hospital, Japan

• Hiroshi Shiku, M.D., Mie University School of Medicine, Japan

• Hisashi Wada, M.D., Ph.D., Osaka University, Japan

Australia• Jonathan S. Cebon, Ph.D.,

FRACP, Austin Health, Ludwig Cancer Research

• Mark J. Smyth, Ph.D., FAHMS, QIMR Berghofer Medical Research Institute


The Clinical Accelerator has a network of nearly 90 leading cancer immunologists across 12 countries, who bring unparalleled expertise to the design, planning, and execution of our clinical trials.

Adam Kolom Clinical Accelerator

YOUNG PHILANTHROPISTS COUNCIL

BOARD

Priyanka SewhaniAll About the OpticsNew York, NY

Catherine BorodPartners & SpadeNew York, NY

Anna-Nora BernsteinFreelance Film ProducerNew York, NY

Ali UrmanMontefiore Medical CenterNew York, NY

Anna Maria BarbutiSt. Johns UniversityNew York, NY

Samuel ObletzGoldman SachsNew York, NY

Marissa KaplanVerathon Inc.New York, NY

Megan BanniganDebevoise & Plimpton LLPNew York, NY

Brittany LettCognitoNew York, NY

MEMBERS

Natalie Berner Linda FoitSean KielyJaskaren RandhawaDiana Rosario

STAFF

SENIOR STAFF

Jill O’Donnell-Tormey, Ph.D.Chief Executive Officer and Director of Scientific Affairs

Brian M. BrewerDirector of Marketing and Communications

Lynne A. HarmerDirector of Grants Administration and Special Events

Alfred R. MassidasChief Financial Officer and Director of Human Resources

Sharon SladeDirector of Strategic Initiatives

STAFF

Arthur N. Brodsky, Ph.D.Science Writer

Rupinder KaurSenior Manager of Operations and Officer of Planned Giving Michelle LiewDigital Media Manager

Melinda LopezReceptionist/Administrative Assistant

Vanessa M. Lucey, Ph.D., MBAAssociate Director, Clinical Venture Fund and Accelerator

Caitlin MackamanManager of Individual Giving

Katherine McCluskeyEvent Coordinator

Shasell NegronGeneral Manager / Workplace Giving Campaign Manager Alexa SchlesGraphic Designer Devi SharmaDonations Processing Manager Marla A. SincavageAssociate Director, Corporate and Foundation Relations Denise UptonManager of Grants Administration Jasmine WrightEvents Coordinator and Assistant to the CEO

Qing Hua ZhangController

CONSULTANT

Adam KolomManaging Director, Clinical Accelerator

CANCER IMMUNOTHERAPY CONSORTIUM

STEERING COMMITTEE CHAIRS

Daniel S. Chen, M.D., Ph.D.GenentechSouth San Francisco, CA

Axel Hoos, M.D., Ph.D.GlaxoSmithKlineCollegeville, PA

MEMBERS

Cedrik M. Britten, M.D.GlaxoSmithKlineStevenage, United Kingdom Roger D. Dansey, M.D.Merck Research LaboratoriesRahway, NJ

Glenn Dranoff, M.D.Novartis Institutes for BioMedical ResearchCambridge, MA

Robert M. Hershberg, M.D., Ph.D.Celgene and VentiRx PharmaceuticalsSeattle, WA

Michael Kalos, Ph.D.Eli Lilly & CompanyNew York, NY

Nils Lonberg, Ph.D.Bristol-Myers SquibbMilpitas, CA

Israel Lowy, M.D., Ph.D.RegeneronTarrytown, NY

Ira Mellman, Ph.D.Genentech, Inc.South San Francisco, CA

David M. Reese, M.D.AmgenThousand Oaks, CA

Arvin Yang, M.D., Ph.D.Bristol-Myers SquibbPrinceton, NJ


The Cancer Research Institute has a long tradition of responsible stewardship of donor funds. We receive the highest marks from charity watchdog groups, including four out of four stars from

Charity Navigator and an “A” grade from CharityWatch. CRI also meets all 20 standards of the Better Business Bureau Wise Giving Alliance. Donors to CRI can be confident that their donation, in any amount, will do the most good possible.

OUTRIGHT GIFTS

Cash Donations by check or credit card may be sent directly to the Cancer Research Institute or processed through our secure website at cancerresearch.org/donate

Property Other Than Cash Donating securities, automobiles, and similar properties can often be a tax-efficient method for making a meaningful gift to CRI. Visit cancerresearch.org/ways-to-give

Workplace Giving Programs Ask your human resources department if your company may have a plan through which you can contribute to CRI, or contact us to learn how to set up a program at your workplace.

Matching Gifts You can contact your human resources department to inquire if your employer matches contributions, or browse our online matching gift database to see if your company is listed at cancerresearch.org/match

Planned Gifts Include bequests made through a living trust or inclusion of the Cancer Research Institute in your will as a beneficiary of cash, securities, or personal property. Your bequest should include the Institute’s federal tax ID number (13-1837442) and a statement such as the following:

“I bequeath to the Cancer Research Institute, a not-for-profit corporation of the State of New York, having its principal office at One Exchange Plaza, 55 Broadway, Suite 1802, New York, New York 10006, the sum of $ for its general operating purposes.”

You should, of course, always consult your attorney and tax advisor for the formal writing of your will and to discuss the tax implications of any form of planned giving. Learn more online at legacy.cancerresearch.org.

Lasting ImpactW

AY

S T

O G

IVE


Community Fundraising Want to hold a bake sale to raise money for cancer research? How about a fashion show, dinner, or a music concert? Maybe you’re getting married and would prefer guests give to charity in lieu of gifts. We offer support for these and other fundraising ideas. Visit cancerresearch.org/fundraise to learn more about how you can organize your own special event and become a part of Team CRI.

FOR CORPORATE PARTNERS

No one organization, company, or group can solve the cancer problem alone. It takes collaboration to change the course of cancer. CRI actively seeks out and welcomes opportunities to work together with others to develop educational and awareness-building programs designed to advance the pace of progress in cancer immunotherapy research. Contact Sharon Slade at [email protected] or (212) 688-7515 x230 to learn more.

ALEXANDER M. LESOKHIN, M.D., A CRI-FUNDED CLINICAL INVESTIGATOR AT MEMORIAL SLOAN KETTERING CANCER CENTER IN NEW YORK, NY, IS TESTING TWO PROMISING CHECKPOINT IMMUNOTHERAPIES, DURVALUMAB AND TREMELIMUMAB, IN A CLINICAL TRIAL FOR PATIENTS WITH MULTIPLE MYELOMA.

To help you make the most fitting and fulfilling contribution to CRI, please contact our Development Office at (212) 688-7515 or send an email to [email protected].

NATIONAL HEADQUARTERSOne Exchange Plaza55 Broadway, Suite 1802 New York, NY 10006Tel. (212) 688-7515Toll-Free (800) 99-CANCERFax (212) 832-9376Email [email protected]

VOLUNTEER OFFICES344 Hauser Boulevard, Unit 422Los Angeles, CA 90036Tel. (323) 935-2520

101 University Avenue, 4th FloorPalo Alto, CA 94301Tel. (650) 365-6441

80 Field Point RoadGreenwich, CT 06830Tel. (203) 622-0522

184 Fisher AvenueBrookline, MA 02445Tel. (617) 566-0100

2802 Flintrock Trace, Suite 220Austin, TX 78738Tel. (512) 610-5530

122 River Run RoadLancaster, VA 22503Tel. (703) 759-0835

CANCERRESEARCH.ORG

Documents

2016 ANNUAL REPORT - CRI - Cancer Research Institute · CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT 1 OUR MISSION: ... aidong Dong, M.D., ... The Anna-Maria Kellen Clinical Accelerator